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ABSTRACT 
Nonalcoholic steatohepatitis (NASH) is the advanced form of nonalcoholic fatty liver 
disease and is the hepatic manifestation of metabolic syndrome.  The overall rate of NASH is on 
the rise globally, and currently approximately 1.5-6.45% of the population is afflicted with this 
disease(Z. M. Younossi et al., 2016).  The progression of NASH is known to result in the 
dysregulation of many genes, including those that are responsible for ADME processes.  These 
changes can alter the disposition of xenobiotics and result in adverse drug reactions (ADRs).  
Since ADRs are becoming increasingly frequent, with nearly 1 in 20 hospital patients 
experiencing ADRs in the United States(Bourgeois, Shannon, Valim, & Mandl, 2010), 
determining the factors that contribute to variations in drug response is increasingly important.  
Additionally, genetic polymorphisms are known to cause pharmacokinetic variations, and many 
of them have been extensively researched for their impacts on patient response.  Less known, 
however, is how genetic polymorphisms and chronic liver disease interact, and how that 
interaction may increase patient risk for ADRs.  As the goal of precision medicine is to provide 
the right dose to the right person at the right time, determining how factors like disease state 
can interact with genetic polymorphisms to alter pharmacokinetics can provide a better basis for 
individualized dosing.  The purpose behind this study was therefore to utilize a methionine- and 
choline-deficient (MCD) rodent model to determine the gene-by-environment interactions of 
hepatic xenobiotic transporter polymorphisms and NASH on the disposition and toxicity of 
pharmaceutical compounds. 
To identify the impact of these gene-by-environment interactions, pharmacokinetic 
studies were designed to investigate the alterations to drug distribution that occurred with NASH 
in combination with disruptions of hepatic uptake and efflux transporters and to determine the 
underlying mechanism behind pharmacokinetic alterations during disease progression.  The 
results in the MCD rodent model of NASH found a synergistic interaction between 
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polymorphisms of both hepatic uptake and efflux transporters and NASH that lead to changes in 
plasma retention and biliary excretion of probe substrates.  The comparison between biliary 
excretion of SN-38 in wild-type and Bcrp-/- rats demonstrated this synergistic interaction, as no 
alterations were found in biliary AUCs until the combination of the disease and genetic 
disruption, where biliary excretion significantly decreased.  A similar interaction was 
demonstrated in a study investigating the gene dose of Oatp1b2 and NASH on pravastatin 
disposition, where the combination of full genetic Oatp1b2 knockout along with NASH was 
necessary to see dramatic increases in plasma AUC and tissue concentrations.  Finally, in order 
to identify the underlying mechanism by which NASH alters pharmacokinetics, the disposition of 
sorafenib-glucuronide was determined in wild-type, Oatp1a/1b cluster knockouts, and Mrp2 
knockouts, with and without MCD diet.  By comparing the changes to plasma AUC and liver 
concentrations in these groups, the disruption to hepatocyte hopping that occurs during NASH 
was made quantifiable.   
In summation, these data identify synergistic gene-by-environment interactions of 
hepatic xenobiotic transporter polymorphisms and NASH, the alterations that these interactions 
cause to drug disposition, and the mechanism by which NASH causes pharmacokinetic 
changes through disruption of hepatocellular shuttling. 
  
13 
 
CHAPTER ONE: TRANSPORTER ALTERATIONS DURING NASH, GENE-BY-
ENVIRONMENT INTERACTIONS, AND THEIR IMPACT ON ADVERSE DRUG REACTIONS 
 
Adverse Drug Reactions 
Adverse drug reactions (ADRs) are one of the leading causes of morbidity and mortality 
and represent 2.7-15.7% of hospital admissions.  ADRs are defined as “an appreciably harmful 
or unpleasant reaction, resulting from an intervention related to the use of a medicinal product, 
which predicts hazard from future administration and warrants prevention or specific treatment, 
or alteration of the dosage regimen, or withdrawal of the product”(Edwards & Aronson, 2000).  
These adverse events can occur in in-patient or out-patient settings.  Out of these admissions, 
28.9% of them were considered preventable(Hakkarainen, Hedna, Petzold, & Hägg, 2012).  
Though many ADRs are not severe and will resolve when the patient is no longer exposed to 
the causative agent, others are debilitating and may result in permanent disability or death and 
represent a significant financial burden on hospital systems.  In 1997, it was estimated that, due 
to the cost associated with increased hospital stays and additional required treatment, each 
ADR had a cost of $2,500 per patient, with a total estimated cost burden of $1.56 billion 
annually(Bates et al., 1997; Classen, Pestotnik, Evans, Lloyd, & Burke, 1997).   
ADRs are classified into two types: pharmacologic or idiosyncratic.  Pharmacologic 
ADRs are the most common type to appear in patients, comprising about 80% of all reported 
ADRs and are usually not life-threatening.  They are also dose-dependent and predictable 
based on the known pharmacological properties of the compound.  There are three major 
causes for this type of reaction: pharmaceutical, pharmacokinetic, and pharmacodynamic.  
Pharmacologic ADRs due to pharmaceutical formulations are generally due to differences in the 
bioavailability or release rate of the compound, while pharmacokinetic ADRs are usually due to 
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variations in ADME processes, and pharmacodynamic ADRs are usually due to variability in the 
sensitivity of drug targets, such as receptor density or affinity(Rawlins, 1981).    
Idiosyncratic ADRs, however, are much less common and are neither dose-dependent 
nor predictable.  Most of the reactions associated with idiosyncratic ADRs appear to be immune 
mediated, as there tends to be a delayed onset of symptoms, but a more rapid onset for 
patients who have been rechallenged(Uetrecht, 2007).  The duration of the delay between 
administration and appearance of symptoms varies depending on the type of reaction; 
dermatological symptoms, the most common kind of idiosyncratic ADRs, generally appear 
within a week, while more severe reactions such as liver injury may be delayed to one or two 
months.  Additionally, drugs that are associated with high numbers of idiosyncratic ADRs often 
precipitate multiple types of reactions.  As an example, carbamazepine can result in liver injury, 
mild skin rash, toxic epidermal necrolysis, agranulocytosis, aplastic anemia, and autoimmunity, 
among other reactions(Jain, 1991; Syn, Naisbitt, Holt, Pirmohamed, & Mutimer, 2005).  It is 
difficult, however, to predict which patients may experience an idiosyncratic ADR, since the 
reactions are specific to the individual.  There have been some weak genetic associations 
between variants of the glutathione-S-transferase enzyme and other metabolic enzymes with 
idiosyncratic drug toxicity, which may indicate that idiosyncratic ADRs are dependent on 
multiple genes(Pirmohamed, 2010).  The exception to this, however, is abacavir 
hypersensitivity, which has been linked to patients with the HLA-B*57:01 variation; 
approximately 50% of these patients will develop an idiosyncratic ADR when given this 
drug(Mallal et al., 2008).  Idiosyncratic ADRs increase the uncertainty involved in drug 
development and further investigation is needed into the potential immune mechanisms that 
govern these ADRs.  
Pharmacogenomics and Precision Medicine 
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Genetic variation plays a significant role in the therapeutic effect of drug treatments, and 
the wide range of genetic diversity that occurs in the human population also results in high 
variability in patient response.  Clinical trials can provide information on the average patient 
response to a drug therapy for a narrow population, but other patient subpopulations may 
experience adverse reactions or no therapeutic benefit from the same dose.  Regardless as to 
whether the result is an ADR or no therapeutic benefit, the impact of these inter-individual 
variabilities can be both expensive and potentially life-threatening.  In order to better predict 
patient response to therapy, pharmacogenomic studies have traditionally focused on variations 
in genes that impact ADME processes, like drug metabolizing enzymes and xenobiotic 
transporters; in recent years, however, due to advances in technology, the focus has shifted to a 
broader range of genetic contributions to ADRs.  By understanding how genetic variations can 
impact the pharmacokinetics or pharmacodynamics of drug therapies, medication regiments 
and dosages can be more appropriately tailored for the individual patient’s needs. 
 
Figure 1.1. Variable platelet response to clopidogrel can associate with risk factors and outcomes. 
On-treatment platelet reactivity in response to clopidogrel can associate with bleeding risk if low or ischemic risk if 
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high, with a therapeutic window. Various risk factors for ischemic heart disease can impact on-treatment platelet 
reactivity in individuals treated with clopidogrel. ACS: acute coronary syndrome; CKD: chronic kidney disease; DM: 
diabetes mellitus.  Brown and Pereira, Journal of Personalized Medicine, 2018, 8.1.  
Genetics, however, are not solely responsible for all inter-individual variabilities seen in 
patient populations.  Non-genetic factors that may impact patient response include lifestyle 
factors such as diet and smoking, as well as factors like concomitant disease, patient 
compliance, age, and ethnicity.  There are many therapies that may have serious 
pharmacologic adverse reactions that can only partly explain their inter-individual variabilities 
through pharmacogenomics.  Many antiplatelet therapies follow this trend; in particular, variants 
in CYP2C19 are associated with an alteration in patient response to the commonly prescribed 
drug clopidogrel.  Approximately one-quarter of patients display reduced response to clopidogrel 
therapy, leaving them at risk for cardiovascular events like heart attack or stroke, and poor 
response to clopidogrel therapy is highly heritable(Cappola & Margulies, 2011).  CYP2C19 is 
responsible for the hepatic bioactivation of clopidogrel, performing 45% of the first step and 20% 
of the second step in the biotransformation of this drug(Brown & Pereira, 2018).  Patients with 
loss-of-function mutations of CYP2C19 may present as poor metabolizers, leading to decreased 
sensitivity and increased risk of blood clots, while those with gain-of-function or multiple 
functional copies of the gene may present as hyper metabolizers, leading to increased 
sensitivity to treatment and a greater risk of hemorrhage.  However, genetic factors, primarily 
involving CYP2C19, only account for approximately 20% of the pharmacokinetic variability and 
65% of the pharmacodynamic variability of clopidogrel therapy(Frelinger et al., 2013).  While 
genetic testing for polymorphisms of CYP2C19 in the case of clopidogrel, or for other enzymes 
and transporters involved in ADME processes for other therapies, have their uses, 
pharmacogenomics cannot precisely predict patient response and a systems biology approach 
for precision medicine will be needed to accurately account for the additional factors that impact 
inter-individual variability.       
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Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis 
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic 
syndrome and consists of a spectrum of liver pathologies ranging from simple steatosis to 
cirrhosis.  It is defined clinically as the presence of >5% of macrovesicular steatosis in the 
hepatocytes of individuals who do not consume much or any alcohol(Loomba & Sanyal, 2013).  
The disease is divided into two histological types: nonalcoholic fatty liver disease, which 
involves the presence of simple steatosis, and nonalcoholic steatohepatitis, which includes the 
presence of inflammation, fibrosis, and necrosis.  Approximately 10-20% of the population is 
estimated to be affected by this NAFLD, and though it is primarily a disease of adults, it has 
been described in pediatric patients.   
Considerable effort has been put into determining the prevalence of NALFD worldwide, 
and current evidence indicates that it is highly prevalent in all populations.  The highest rates of 
NAFLD are reported in South America and the Middle East (31% and 32%, respectively), Asia 
(27%), the United States (24%), and Europe (23%), with the lowest rates described in Africa 
(14%)(Lazo et al., 2013; Schneider, Lazo, Selvin, & Clark, 2014).  In the United States, NAFLD 
prevalence can also vary significantly by ethnic group, with the highest reported rates of NAFLD 
in Hispanic Americans, followed by European-descent Americans, with the lowest reported rates 
in African Americans(Z. Younossi et al., 2018).  While the root of these ethnic disparities is 
unclear, several genetic, environmental, and social factors may be responsible, including factors 
such as comorbid conditions and access to healthcare.   
Even among ethnic groups, there may be differences in the prevalence of NAFLD based 
on the country of origin.  In a study involving the Multi-Ethnic Study of Atherosclerosis (MESA) 
cohort, the prevalence of NAFLD in Hispanic Americans was found to vary significantly 
depending on their country of origin.  Overall, the incidence of NAFLD was 29% among 
Hispanics, but Hispanics of Mexican origin were found to have higher rates of the disease 
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(33%), compared to Hispanics of Puerto Rican origin (19%) or Dominican origin 
(16%)(Fleischman, Budoff, Zeb, Li, & Foster, 2014).  Given that the term Hispanic can refer to a 
collection of individuals that is culturally and genetically diverse, it is too non-specific to function 
as an umbrella term regarding the propensity to develop NAFLD and therefore assumptions of 
homogeneity cannot be made when performing risk assessment in Hispanic populations.   
NASH, the advanced form of NAFLD, was originally coined in 1980 by Ludwig et al. in 
their groundbreaking paper that described the histological findings that are characteristic of the 
disease: steatosis, inflammatory infiltrates, fibrosis, cirrhosis, and Mallory bodies(Ludwig, 
Viggiano, McGill, & Oh, 1980).  As NASH can currently only be definitively diagnosed through a 
liver biopsy, determining the prevalence of this disease in any given population has inherent 
challenges.  In the United States, however, the estimated incidence of NASH is around 1-
3%(Sayiner, Koenig, Henry, & Younossi, 2016a).  In an autopsy study conducted in 1990, 
18.5% of obese patients were found to have NASH, while only 2.7% of lean patients had 
evidence of the disease(Wanless & Lentz, 1990).  Diabetes, dyslipidemia, hypertension, and 
obesity remain high risk factors for the development of NAFLD and NASH; in studies involving 
Italian and UK cohorts with type-2 diabetes, incidence rates of NAFLD were found to be 60-70% 
and 42.6%, respectively(Soresi et al., 2013; Williamson et al., 2011).   
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Figure 1.2.  Histology of human NAFLD. H&E staining of FFPE human liver samples diagnosed as 
normal, steatotic, NASH (fatty), and NASH (not fatty), shown at magnification 20×. Diagnoses: steatosis, >10% fatty 
infiltration of hepatocytes with microvesicular steatosis (black arrow); NASH (fatty), >5% fatty infiltration with 
macrovesicular steatosis (white arrow), inflammation, and fibrosis; NASH (not fatty), <5% fatty infiltration with more 
significant inflammation and fibrosis (*). Hardwick et al., Drug Metab. Dispos. 2011, 39, 2395-2402. 
NASH is considered a complex disease, as it has no one single genetic variation or 
origin that is associated with its pathogenesis.  Several molecular mechanisms underlie the 
pathogenesis of NAFLD and NASH, including perturbations of free fatty acid (FFA) packaging, 
mitochondrial dysfunction, oxidative stress and inflammation, and fibrinogenesis.   
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Lipotoxicity 
The liver is a major site of lipid metabolism, and is the major organ that imports, 
manufactures, stores, and packages lipids.  Perturbation of any of these processes could lead 
to dysfunctional lipid processing and subsequently contribute to the development of NAFLD.  
While fatty acids (FAs) are important for regular cellular function and are required for processes 
such as forming lipid membranes and cellular signaling, chronically elevated FAs can cause 
disturbances in metabolic pathways and is highly associated with insulin resistance(Buzzetti, 
Pinzani, & Tsochatzis, 2016).  Insulin resistance in the peripheral adipose tissue in particular 
increases lipolysis and the delivery of FFAs to the liver; this process can be exacerbated by 
obesity, which increases the expression of tumor necrosis factor α (TNFα) in adipocytes, 
enhances adipocyte insulin resistance, and increases the rate of lipolysis(Morigny, Houssier, 
Mouisel, & Langin, 2016).  Under normal circumstances, excess FFAs would stimulate the 
synthesis of triglycerides (TGs), which would then be stored within hepatocytes in droplets or 
secreted into the blood as very-low-density-lipoprotein (VLDL)(Buzzetti et al., 2016).  The 
excessive accumulation of hepatic triglycerides in NAFLD and NASH are associated with the 
increased pool of FFA from peripheral adipocytes and increased de novo lipid synthesis, as well 
as increased VLDL production and β-oxidation of FAs(Paglialunga & Dehn, 2016; Saponaro, 
Gaggini, & Gastaldelli, 2015).  These abundant FFAs in NAFLD then causes lipotoxicity through 
the induction of ROS release, leading to inflammation, cell death, fibrosis, and the progression 
of the disease to NASH(Ibrahim, Kohli, & Gores, 2011). 
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Figure 1.3. ‘‘Multi—hit’’ hypothesis: pathogenesis of NAFLD. In this model, dysregulated free fatty acid 
(FFA) metabolism (the ‘‘first hit’’) results in lipid accumulation in the liver, producing steatosis. Inflammatory 
mediators, reactive oxygen species, and abnormal apoptotic mechanisms serve as ‘‘second hits’’ that result in 
superimposed inflammation (NASH). The interplay between inflammatory mediators and the activation of stellate cells 
can lead to fibrosis that, left unchecked, will overcome the regenerative capacity of the liver, producing cirrhosis. 
Edmison et al., Clin Liver Dis, 2007, 11.1, 75–104. 
In addition to the alterations to lipid metabolism that occur during NAFLD,  hepatic 
mitochondria are structurally and molecularly altered, and the decline in mitochondrial function 
may exacerbate metabolic disturbances and drive disease progression(Simões, Fontes, Pinton, 
Zischka, & Wieckowski, 2018).  FAs are oxidized within the mitochondria, peroxisomes, and the 
endoplasmic reticulum (ER), and while short and medium-chain FAs can pass the mitochondrial 
membrane, long-chain FAs (LCFA) require activation in the cytosol by acetyl-COA and transport 
across the membrane via carnitine palmitoyltransferase-1 (CPT1)(Berlanga, Guiu-jurado, 
Porras, & Auguet, 2014).  In NAFLD, the increased pools of FFA increases the burden of 
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oxidation and TCA cycle stimulation on hepatic mitochondria, promoting the formation of 
superoxides through the over-reduction of respiratory complexes(Aharoni-simon, Hann-
obercyger, Pen, Madar, & Tirosh, 2011).  Mitochondrial damage can occur once the 
superoxides are enzymatically converted into hydrogen peroxide.  Additionally, during FA 
overload, ω-oxidation of LCFAs induces ROS formation and lipid peroxidation in the 
ER(Berlanga et al., 2014).  To compensate for the increase in ROS formation, upregulation of 
PPARα and UCP-2 occurs to increase fatty acid oxidation and increase the activity of the 
electron transport chain to limit the further production of ROS, respectively.  This adaptive 
response, however, also decreases the proton gradient and hampers ATP production, leaving 
the hepatocytes vulnerable to ATP depletion and necrosis, as has been observed in NASH 
patients(Cortez-Pinto et al., 1999; Koek, Liedorp, & Bast, 2011). 
Peroxisomal β-oxidation of FFAs are responsible for the formation of acetyl-COA, which 
is transported to the mitochondria for further degradation.  Peroxisomal genes involved in lipid 
metabolism are controlled by PPARα, and increased expression of these genes is associated 
with the induction of peroxisome proliferation.  This increase in the number of peroxisomes in 
the hepatocyte increases the cell’s capacity to oxidize FFAs, leading to a higher production of 
H2O2 that can be converted to highly reactive hydroxyl radicals.(Koek et al., 2011; Pawlak, 
Lefebvre, & Staels, 2015) 
Lipid peroxidation is the oxidative degradation of lipids that occurs when an electron is 
stolen from an unsaturated fatty acid, resulting in lipid peroxides.  This can result in membrane 
disruption and the formation of reactive products like malondialdehyde (MDA) and 4-hydroxy-
2,3-transnonenal (4-HNE), which can themselves cause damage through the formation of 
deleterious DNA adducts(Koek et al., 2011).  Both MDA and 4-HNE are used as biomarkers of 
lipid oxidation, and these biomarkers have been found in higher levels in up to 90% of NASH 
patients when compared to patients with steatosis.  4-HNE is primarily found in the cytoplasm of 
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hepatocytes and sinusoidal cells and correlates well with the histological grade of 
inflammation(Ucar et al., 2013).    
Hepatic iron accumulation may contribute to disease progression through the production 
of reactive oxygen species.  Iron can catalyze the conversion of peroxides into hydroxy and 
hydroperoxyl radicals, which are highly reactive and can cause significant oxidative damage in 
cells(Yang & Stockwell, 2016).  Patients with chronic liver disorders such as chronic hepatitis C, 
NAFLD, NASH, and cirrhosis exhibit increased hepatic iron deposition even in the absence of 
mutations in the hemochromatosis gene (HFE).  There are three primary patterns of hepatic iron 
deposition: exclusively in hepatocytes, exclusively in the reticuloendothelial system (RES) cells, 
or distributed throughout both hepatocytes and RES cells(Nelson et al., 2011).  Hepatic iron 
accumulation in patients with cirrhosis or secondary iron overload generally begins in the RES 
cells, while deposition in patients with NAFLD, NASH, or chronic hepatitis C may occur in any 
pattern(Batts, 2007; Y., 2007).  The role that iron plays in liver disease progression, if any, is 
unclear, though several studies have insinuated a relationship between hepatic iron loading and 
disease stage in hepatitis C patience and iron deposition in the RES cells and advanced fibrosis 
in alcoholic liver disease(Kohgo et al., 2005; Price & Kowdley, 2009).  In NAFLD and NASH 
patients, those with the RES iron staining pattern were significantly more likely to have 
advanced fibrosis than those with the hepatocyte staining pattern were also more likely to have 
advanced histological features such as fibrosis, portal inflammation, and a definitive NASH 
diagnosis(Nelson et al., 2011).  This indicates that the presence and pattern of iron deposition in 
patients with NAFLD and NASH plays a role in disease pathogenesis and may represent a 
potential avenue of therapeutic intervention. 
Antioxidant Response 
In normal physiological conditions, reactive oxygen species would be resolved by ROS 
detoxification mechanisms like SOD2, catalase, or GSH, or through reduction in substrate 
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delivery to the TCA cycle.  However, there is evidence to suggest that antioxidant response 
pathways are dysfunctional in patients with NASH and other chronic liver diseases, resulting in 
unconstrained damage from ROS.  The decreased expression of antioxidant factors such as 
coenzyme Q10, catalase, Cu/Zn superoxide dismutase (SOD1), glutathione, and glutathione S-
transferase are shown to correlate with disease severity(LECLERCQ, 2004), and patients with 
NAFLD and NASH have been observed to have lower hepatic GSH:GSSG ratios than healthy 
patients, indicating a higher burden of oxidative stress(R. N. Hardwick, Fisher, Canet, Lake, & 
Cherrington, 2010).  It should be noted that there does not appear to be dysfunctional GSH 
synthesis during the progression of the disease; NRF2 activation appropriately occurs in 
response to oxidative stress, as has been evidenced through nuclear immunohistochemical 
staining of NRF2, leading to increased expression of antioxidant response proteins like NQO1, 
GST isoforms, GCLC, and GCLM following disease progression.  However, the activity of 
enzymes like GST appears to be decreased in NAFLD and NASH patients(R. N. Hardwick et 
al., 2010), indicating that the impairment of the antioxidant response may lie in the dysfunction 
of particular antioxidant defense enzymes rather than in dysregulation of expression.   
Inflammatory Response 
Liver inflammation leads to hepatic damage and the formation of fibrosis and is one of 
the major drivers of NASH disease progression.  The presence of inflammatory cytokines may 
play a central role in the progression of NAFLD to NASH.  Evidence suggests a correlation 
between the circulating levels of tumor necrosis factor-α (TNFα) and the severity of steatosis, 
inflammation, necrosis, and fibrosis(Marra, Gastaldelli, Svegliati Baroni, Tell, & Tiribelli, 2008).  
Similarly, interleukin-6 (IL-6) levels in the blood and liver of NASH patients was significantly 
elevated when compared to those with steatosis or normal biopsies, and positively correlated to 
the degree of inflammation, stage of fibrosis, and degree of systemic insulin 
resistance(Wieckowska et al., 2008).  Chronic IL-6 exposure will also cause chronic activation of 
25 
 
the JAK-STAT pathway, which is controlled through a negative feedback loop via the 
suppresors of cytokine signaling (SOCS) family.  SOCS family members also can interfere with 
insulin-receptor and leptin-receptor signaling, thus depicting a potential link between liver 
inflammation, insulin resistance, and obesity(Howard & Flier, 2006).  ROS and lipid peroxides 
are factors that can contribute to the generation of inflammatory signals that ultimately result in 
neutrophil chemotaxis and the hepatic lesions associated with NASH(Marra et al., 2008).  These 
ROS can also activate the NF-κB pathway, thus inducing the expression of TNFα and also 
resulting in an elevation of the levels of other cytokines, such as the transforming growth factor-
β (TGFβ), IL-6, IL-8, and Fas ligand(Rolo, Teodoro, & Palmeira, 2012).  Additionally, this 
activation of TNFα can further exacerbate oxidative stress in the liver by causing additional lipid 
peroxidation of mitochondrial membranes and also induces NADPH oxidase (NOX) activity, 
which leads to an inflammatory response through tumor necrosis factor receptor-1 (TRF-1) 
expression and NF-κB activation(Koek et al., 2011).  TNFα and TGF-β are also involved in the 
formation of Mallory bodies, a common histological feature of NASH, and in the activation of 
stellate cells that induce fibrotic formation(Mehta, Van Thiel, Shah, & Mobarhan, 2002).   
Fibrosis formation by stellate cells can also be up-regulated through glucose and insulin, 
indicating a possible link between diabetes, hyperinsulinemia, and liver fibrosis in NASH(Koek 
et al., 2011).   
Other proinflammatory factors that may contribute to the inflammatory response in the 
fatty liver include the pattern-recognition receptor (PRR) family.  These receptors consist of Toll-
like receptors (TLRs) and other receptors that can recognize bacterial products and activate a 
variety of pathways, including the NF-κB pathway, further exacerbating and maintaining the 
presence of inflammatory mediators and fibrosis formation(Schwabe, Seki, & Brenner, 2006; 
Seki et al., 2007).   
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NALFD and NASH is rapidly becoming the most common chronic liver condition 
worldwide due to the rising rates of obesity in both adult and pediatric patients.  The progression 
of this disease is a complex interplay between lifestyle, the environment, and genetic factors, 
though there is not yet a full understanding of its pathogenesis.  No drug therapies currently 
exist to ameliorate NASH, though the presence of NASH has significant implications for the drug 
therapies involved in the management of conditions that are comorbid with the disease. 
ADME in the Liver 
The liver is the major organ of metabolism of endogenous and xenobiotic compounds 
through phase 1 modification and phase 2 conjugation reactions and subsequent elimination 
through xenobiotic transporter proteins.  While some compounds are capable of diffusing across 
the membrane, many large, polar compounds can only enter the hepatocyte through active 
transport.  Endogenous substrates of hepatic transporters include coproporphyrins, bile acids, 
bilirubin, and hormones such as estrone sulfate, while exogenous substrates include statin 
drugs, chemotherapeutics such as methotrexate and paclitaxel, and antimicrobials such as 
caspofungin and rifampin(König, 2011; Takehara et al., 2018).  Hepatic uptake is mainly 
mediated through transporters of the SLC (solute carrier) family, including the organic anion 
transporting polypeptides OATP1B1, OATP1B3, OATP1A2, and OATP2B1; the organic anion 
transporter OAT2; the sodium/bile acid cotransporter NTCP; and the organic cation transporter 
OCT1 in humans(Giacomini et al., 2010) (fig.1.4).     
The liver plays an important role in protecting against chemical insults via its ability to 
convert lipophilic compounds into more hydrophilic metabolites that can be excreted into urine 
or bile.  Its capacity for these detoxification steps is due to the expression of a large number of 
drug metabolizing enzymes which allow for the oxidation, reduction, and hydrolysis in the case 
of phase 1 metabolism, and conjugation in the case of phase 2 metabolism.  Phase 1 
metabolism is mostly mediated by cytochrome P450 (CYP) enzymes, but may also involve other 
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enzymes like oxidases, peroxidases, hydrolases, and esterases.  The end result of phase 1 
metabolism is usually either the exposure or addition of a functional group that may later 
become the target of phase 2 conjugation.  During conjugation reactions, the labile functional 
groups, usually carboxyl, hydroxyl, amino, or sulfhydryul groups, will be modified by a charged 
species such as GSH, sulfate, or glucuronic acid, resulting in the detoxification of reactive 
electrophiles and also a large, polar metabolite that cannot diffuse across plasma membranes.  
These conjugated metabolites generally require active transport to be excreted into bile or urine. 
 
Figure 1.4.  Hepatic uptake and efflux transporters.  Compounds are taken into hepatocytes from the 
blood via the sinusoidal uptake transporters.  Transporters on the bile canaliculus export compounds and their 
metabolites into the bile for excretion. Sinusoidal efflux transporters export compounds metabolites from hepatocytes 
into blood.   
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The active transport of compounds into bile or urine is usually facilitated through 
transporter proteins of the ATP binding cassette transporter family.  Among the many 
functionally diverse transporters contained within this group, however, only some of them are 
relevant to the transport of pharmaceutical drugs: P-glycoprotein (P-gp), breast cancer 
resistance protein (BCRP), and the multidrug resistance proteins 1-5 (MRPs).  These 
transporters are localized to either the plasma membrane or the bile canaliculuar membrane, 
where they participate in the export of compounds either into blood or into bile in an active, 
ATP-dependent manner (fig.1.4).     
Drug efflux transporters can be divided into four classes based on predicted two-
dimensional structure and amino acid sequence homology.  The first of these classes is based 
on the structure of P-gp, which consists of two domains of six transmembrane segments each 
with two nucleotide binding domains, N-glycosylated at the first extracellular loop.  The second 
class contains MRP1, 2, and 3, which have an additional 5-member transmembrane domain at 
the N-terminus, with N-glycosylation at the sixth extracellular loop and the N-terminus.  The third 
class contains MRP4 and 5, which lack the extra 5-member transmembrane domain of MRP1, 
2, and 3 and instead are N-glycosylated at the fourth extracellular loop.  The fourth class 
contains BCRP, which is a half-transporter that consists of a single six-member transmembrane 
domain and one nucleotide binding domain at the N-terminus. (Schinkel & Jonker, 2012)   
While the function of drug metabolizing enzymes and xenobiotic transporters is 
important for the timely detoxification and elimination of compounds, they can also be the site 
for drug-drug interactions when multiple compounds compete for enzymatic activity or transport.  
DMEs may also be responsible for the production of reactive metabolites that can result in off-
target effects, including toxicities.  Some drugs are also activated through hepatic metabolism, a 
process known as bioactivation, and a lack of timely bioactivation could result in decreased 
therapeutic effect.  Alterations to the expression of DMEs and xenobiotic transporters, whether 
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via transcriptional, translational, or post-translational means, could therefore have a significant 
impact on the metabolism and elimination of compounds. 
Regulation of DMEs 
Drug metabolizing enzymes, such as those within the cytochrome P450 family (CYPs), 
are particularly relevant for clinical pharmacology, and significant pharmacokinetic and 
pharmacodynamic variability stems from the expression and function of these enzymes (fig.1.5).  
While polymorphisms explain some of the variability seen in enzymatic activity, other factors are 
also involved in the regulation of DMEs, including polymorphisms of regulatory genes, age, sex, 
xenobiotic exposure, and disease state.  Though many CYP450 enzymes have overlapping 
substrate specificity, many clinically relevant compounds are only metabolized to a significant 
degree by a few enzymes, which limits the redundancy in the phase I oxidation system and 
increases the importance of enzyme expression, function and activity on predicting drug 
response(Zanger & Schwab, 2013). 
There have been decades of research into the heritable genetic variation in DMEs, and 
there are many examples of clinically relevant variants.  In CYP genes, the majority of variants 
that impart a loss of function do not impact transcription or protein structure, but rather cause 
aberrations in splicing and expression(Sadee et al., 2011).  Variations that induce a gain of 
function in these enzymes generally involve an increase in copy number variants, promoter 
variants, and amino acid variants with increased substrate turnover, while few involve 
aberrations in substrate selectivity or pathway inducibility(Johansson & Ingelman-Sundberg, 
2008; Zanger & Schwab, 2013).  Clinically, polymorphisms of DMEs can have significant 
impacts on pharmacokinetics and pharmacodynamics; loss-of-function variants may result in 
prolonged exposure while gain-of-function variants may result in decreased efficacy of any 
given therapeutic, and vice-versa in the case of prodrugs that require bioactivation.   
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Figure 1.5. Fraction of clinically used drugs metabolized by P450 isoforms and factors influencing variability. 
Important variability factors are indicated by bold type with possible directions of influence indicated (↑, increased 
activity; ↓, decreased activity; ↑↓, increased and decreased activity). Factors of controversial significance are shown 
in parentheses.  Zanger and Schwab, Pharmacology and Therapeutics, 2013, 138.1, 103-141. 
Not all heritable variations involve an alteration to the DNA sequence of a gene.  
Epigenetic variations can control gene expression through DNA methylation, histone 
modification, and through microRNA (miRNA) regulation.  In general, DNA methylation of 
promoter regions suppresses the expression of the target gene by inhibiting transcription factor 
binding or recruiting methyl‐CpG‐binding proteins that alter chromatin structure.  For many 
DMEs, there is an inverse correlation between mRNA expression and DNA methylation, 
including with CYP1A2, CYP2C19, CYP2D6, GSTA4, GSTM5, GSTT1, and SULT1A1, as 
observed in adult human liver(Habano et al., 2015).  For certain enzymes, such as CYP3A4, 
hepatic expression is highly variable in humans, but there are few genetic variations that 
contribute significantly to this variability.  While it has been previously shown that methylation of 
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the promoter site of CYP3A4 has little impact on gene expression, methylation at CpG sites 
near or within transcription factor binding sites does correlate with the expression of CYP3A4 in 
adult human liver(Fisel, Schaeffeler, & Schwab, 2016; Habano et al., 2015; Kacevska et al., 
2012).  In addition to DNA methylation, miRNA can also regulate gene expression, usually 
through binding to a section of the 3’UTR segment of a target gene, causing an inhibition of 
translation or cleavage of the target mRNA and reduced expression of the protein.  miRNA 
posttranscriptional regulation has been observed in DMEs; the broadly conserved miR-27b 
targets, among others, the 3’UTR of CYP3A4 and CYP1B1, downregulating the protein and 
mRNA expression of these enzymes, while CYP2E1 is negatively regulated by miR-378, but 
through translational repression rather than mRNA degradation.(Pan, Gao, & Yu, 2009; Yokoi & 
Nakajima, 2013).  Even outside of direct modulation of gene expression, miRNAs can indirectly 
modulate expression by regulating nuclear receptors and other transcription factors like PXR, 
NRF2, and PPARs(Y. Chen, Xiao, Zhang, & Bian, 2016; Yokoi & Nakajima, 2013).   
DME expression at the transcriptional level is largely mediated through various 
transcription factors.  These regulatory proteins generally contain a highly conserved DNA 
binding domain that allows for binding to promoter regions of target genes, and a variable 
ligand-binding domain that allows for the interaction between the protein and a wide range of 
endogenous or exogenous compounds.  A number of nuclear receptor transcription factors, 
notably farnesoid X receptor (FXR), liver X receptor (LXR), proxisome proliferator activation 
receptors (PPARs), constitutive androstane/active receptor (CAR), pregnane X receptor (PXR), 
nuclear factor-erythroid 2-related factor 2 (NRF2), and aryl hydrocarbon receptor (AhR), bind 
xenobiotics such as pharmaceuticals and environmental toxicants, and their activation results in 
the upregulation of genes that encode for phase I and phase II DMEs(Tolson & Wang, 2010).   
Regulation of Transporters 
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Similar to DMEs, hepatic transporter expression is regulated by a number of different 
mechanisms, including transcription factors, genetic polymorphisms, epigenetic modifications, 
and miRNAs.  A solid understanding of the mechanisms of transporter regulation is of potential 
importance to more accurately predict pharmacokinetics and variable drug responses in human 
populations. 
Genetic polymorphisms of hepatic uptake and efflux transporter proteins have been 
extensively studied with regards to their potential impact on the pharmacokinetics of 
xenobiotics.  There are multiple variants of OATP uptake transporters that are known to cause 
alterations to the pharmacokinetics or drug responses of substrates, including the reduction-of-
function c.521T>C variant of SLCO1B1, which increases the risk of statin-induced myopathy, 
and the c.1683-5676A>G reduction-of-function variant of SLCO1B3, which has been associated 
with an increased risk of docetaxel-induced neutropenia(Franke, Gardner, & Sparreboom, 2010; 
Maeda, 2015).  Polymorphisms of efflux transporters can also result in significant 
pharmacokinetic alterations; the c.24C>T variant of ABCC2 alters the volume of distribution and 
clearance rate of methotrexate in human patients, and the c.421C>A variant of ABCG2 is 
significantly correlated with altered erlotinib clearance in Japanese lung cancer patients(Fukudo 
et al., 2013; Simon et al., 2013).   
Beyond DNA sequence variation, epigenetic control mechanisms like methylation of 
genomic DNA, histone modification, and regulatory noncoding RNAs can alter gene expression 
of hepatic transporter proteins.  Methylation of the ABCB1 promoter region has been shown to 
inversely correlate with mRNA expression.  Similarly, methylation of the ABCG2 promoter 
region also decreases mRNA expression in myeloma patients, and also the binding of methyl-
CpG binding domain proteins to CpG islands of this gene alters acetylation and therefore 
modulates gene expression(Kim, Han, Burckart, & Oh, 2014).  Additionally, miRNAs participate 
in the posttranscriptional regulation of uptake and efflux transporters.  Over a dozen miRNAs 
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are known to regulate the expression of ABCB1, including miR-27a and miR-451 and the 
expression of ABCC2 is regulated through miR-297, miR-379, and let-7c.  SLC16A1 has also 
shown to be regulated by miR-124 and miR-29a/b(Yu, Tian, Tu, Ho, & Jilek, 2016).  These 
miRNAs alter the mRNA and protein expression of these genes, as well as the protein function.   
Transcription factors are a major factor in the transcriptional regulation of hepatic 
xenobiotic transporter genes.  The activation of transcription factors such as the aryl 
hydrocarbon receptor (AhR), constitutive androstane receptor (CAR), pregnane X receptor 
(PXR) and nuclear factor E2-related factor 2 (Nrf2) plays a significant role in the expression of 
efflux and uptake transporters in the liver.  Many ADME-related genes, including some 
xenobiotic transporters, contain antioxidant response elements (AREs) and therefore are 
impacted by the redox-sensing NRF2 transcription factor, including Abcg2, Abcc2, Abcc3, and 
Abcc4, which show significant downregulation of mRNA expression in Nrf2-null mice(Reisman, 
Csanaky, Aleksunes, & Klaassen, 2009).  This is supported in human primary hepatocyte cell 
culture assays, where Jigorel et al. determined that the mRNA expression of MDR1 (P-gp), 
ABCG2, ABCC2, and ABCC3 were upregulated by incubation with oltipraz (OPZ), a known 
NRF2 activator.  In addition to NRF2 inducers, ABCG2 and MDR1 were upregulated by 
treatment with dioxin (TCDD, an AhR activator) and rifampicin (RIP, a PXR activator), and 
ABCC3 was also upregulated after exposure to RIP.  The bile acid transporters ABCB11 and 
SLC10A1 and the sinusoidal uptake transporter SLC22A7, conversely, were downregulated 
after exposure to OPZ, RIP, TCDD, and phenobarbital (PB, a CAR activator).  Other uptake 
transporters also become downregulated in the presence of transcription factor activators, 
including SLC22A1 and SLCO1B3 via PB, TCDD, RIF, and OPZ and SLCO2B1 via PB and 
TCDD.(Jigorel, Le Vee, Boursier-Neyret, Parmentier, & Fardel, 2006)  Transporter regulation 
through transcription factor activation is a complicated process, and many transporters can be 
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regulated through multiple pathways, allowing for significant inter-individual variability among 
humans.     
ADME Remodeling in NASH 
A 2011 study involving human liver biopsies from patients who had confirmed diagnoses 
of steatosis, fatty NASH, or non-fatty NASH were analyzed using an AffyMetrix GeneChip to 
determine altered mRNA expression when compared to normal patients.  This study found that 
11,633 genes were dysregulated during the progression of NASH, including a variety of genes 
that are important to ADME processes, such as drug metabolizing enzymes and xenobiotic 
transporters(Lake et al., 2011).  Many different pathways were found to be altered during the 
progression of this disease, including those involved in endoplasmic reticulum stress, 
antioxidant response, and N-linked glycosylation of proteins(Clarke, Novak, Lake, Hardwick, & 
Cherrington, 2016; R. N. Hardwick et al., 2010; Lake et al., 2013).  While previous studies have 
examined the gene expression of various pathological groups related to NAFLD and NASH, this 
study notably compares all three pathological groups (normal, steatosis, and NASH), and 
therefore is able to determine global gene expression alteration patterns across disease 
progression.  In this way, the study was able to identify that the majority of gene expression 
alterations occur during the progression from steatosis to NASH, and not from the progression 
of normal to steatosis(Lake et al., 2011).  In particular, the pairwise comparison of over 500 
transporter genes revealed significant trends in the expression of uptake and efflux transporters 
in NASH.  The hepatic uptake transporter genes showed significant enrichment for 
downregulation, which may represent a protective mechanism in the liver by which it attempts to 
prevent the accumulation of toxic compounds or metabolites by limiting hepatic uptake; this is 
bolstered by studies in mouse models that reveal similar transporter alterations in the presence 
of toxic doses of acetaminophen and carbon tetrachloride(Aleksunes et al., 2004; Lake et al., 
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2011).  Conversely, the hepatic efflux transporters showed significant upregulation during the 
progression of NASH, further coinciding with other research that determined that there is a  
concomitant upregulation of efflux transporter mRNA during hepatotoxicant exposure in mouse 
models(Aleksunes, Scheffer, Jakowski, Pruimboom-Brees, & Manautou, 2005; Lake et al., 
2011). 
The Cherrington group has put a significant amount of effort into determining the specific 
alterations to drug metabolizing enzymes that occur during the progression of NASH and their 
potential impact on pharmacokinetics.  As the cytochrome P450 enzyme family is responsible 
for the majority of xenobiotic metabolism in the liver, alterations to the mRNA and protein 
expression of these enzymes during the progression of NASH could have significant 
pharmacokinetic consequences.  As the CYP1, CYP2, and CYP3 families are responsible for 
about 75% of the biotransformation of pharmaceuticals in humans, determining the impact of 
disease state on their function is of particular importance.  In adult human patients, CYP1A2, 
2C19, and 2E1 show decreased mRNA expression, while CYP2A6, 2B6, and 2C9 show 
increased mRNA expression with respect to disease progression.  Following mRNA expression, 
CYP2A6 protein expression is also increased during the progression of NAFLD; CYP2B6 and 
CYP2C9 show no significant changes, however.  CYP1A2, 2C19, and 2E1 show decreased 
protein expression following the mRNA trend, and additionally, CYP2C8, 2D6, and 3A4 also had 
decreased expression(Fisher, Lickteig, Augustine, Ranger-Moore, et al., 2009).  When probe 
substrates were used to determine enzymatic activity, CYP1A2, 2C19, 2D6 and 3A4 exhibit 
decreased function, while CYP2A6 and 2C9 showed increased function(Fisher, Lickteig, 
Augustine, Ranger-Moore, et al., 2009).  The discrepancies between alterations to mRNA 
expression and protein expression are likely due to post-translational and other forms of 
regulation.  In pediatric populations, though there are similar cardiovascular and metabolic risk 
factors, there are differences certain histological features, potentially due to differences in 
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toxicant exposures and pubertal hormone levels that may result in alterations to 
pathogenesis(Crespo, Lappe, Feldstein, & Alkhouri, 2016).  The activity of CYP enzymes was 
determined in a pediatric population, and the only enzyme that was significantly changed during 
the progression of the disease was CYP2C19, which was significantly decreased in NASH 
pediatric patients(Li, Canet, et al., 2017).  This is different from the enzyme alterations found in 
adult NASH patients, implying that pediatric and adult NASH are distinct and adolescent 
populations should be treated as a separate at-risk group from adults.      
 
Figure 1.6.  Alteration to hepatic uptake and efflux transporters during NASH.  Protein expression fo 
hepatic uptake transporters experience a general downregulation during NASH, while efflux transporters are 
generally upregulated.  MRP2 protein becomes mislocalized from the bile canaliculus during NASH.  No human 
protein data available for gray transporters.    
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Drug transporter proteins modulate the movement of endo- and xenobiotics and their 
metabolites into and out of cells; significant alterations to these proteins on the transcriptional or 
translational level could therefore cause potentially detrimental changes to the pharmacokinetics 
and pharmacodynamics of compounds.  The Cherrington lab has extensively mapped the 
alterations that occur to clinically relevant xenobiotic transporters of the SLC and ABC 
transporter families and the impact that these changes have on drug distribution and toxicity 
(fig.1.6).  Many of the SLC transporters, such as OATPs, OATs, and OCTs, are located on the 
plasma membrane of hepatocytes and facilitate the uptake of compounds from circulation into 
the cell.  A single SNP in one of these transporters can significantly impact the 
pharmacokinetics of its substrates; during the progression of NASH, not one, but multiple 
transporters are dysregulated.  Previous research found that in human patients, the protein 
expression of OATP1B1 was significantly increased during the course of the disease, while 
OATP1B3 was significantly decreased and OATP2B1 remained unchanged(Clarke et al., 2014).  
For the ABC efflux transporters, a general trend of upregulation was observed; the mRNA 
expression of ABCB1, ABCC1, ABCC3, ABCC4, ABCC5, and ABCG2 were significantly 
increased in the progression of the disease, while only ABCC6 showed downregulation and 
ABCC2 remained unchanged.  The protein expression, however, increases for all of these 
transporters.(R. N. Hardwick, Fisher, Canet, Scheffer, & Cherrington, 2011)  This trend of 
decreased hepatic uptake transporters and increased hepatic efflux transporters that has been 
found in human patients bolsters the concept that ADME remodeling during the progression of 
NASH is a protective mechanism to try to prevent further hepatic injury. 
 As remodeling during NASH impacts the expression of various hepatic transporter 
proteins, there is ample evidence that these changes the pharmacokinetics of substrate 
xenobiotics.  In animal models of NASH, the pharmacokinetics of ezetimibe, morphine-
glucuronide, pemetrexed, metformin, and methotrexate have altered metabolism and excretion 
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during the progression of the disease(Clarke et al., 2015; A. L. Dzierlenga et al., 2015; Anika L 
Dzierlenga et al., 2016; R. Hardwick et al., 2014; R. N. Hardwick, Fisher, Street, Canet, & 
Cherrington, 2012).  These changes generally resulted in an increase in plasma concentrations 
of xenobiotics and a shift from biliary excretion to urinary excretion; this can also result in a 
similar shift in toxicity.  This toxicity profile shift can be seen with methotrexate; rats with MCD 
diet-induced NASH that were given a dose of methotrexate experienced decreased biliary 
excretion and increased plasma retention when compared to controls.  These rats also exhibited 
less intestinal injury, but had increased renal toxicity(R. Hardwick et al., 2014).  When normal 
mechanisms of metabolism and elimination become dysregulated, the risk of toxicity 
significantly increases. 
Hepatocyte Hopping and NASH     
Under normal physiological conditions, a blood-to-hepatocyte-to-blood shuttling 
mechanism known as hepatocyte hopping allows for efficient detoxification of compounds via 
multiple changes at metabolism and excretion.  This mechanism, which was first described by 
the Schinkel group in 2012, involves three main processes: 1) MRP3 sinusoidal efflux, 2) MRP2 
biliary efflux, and 3) OATP sinusoidal uptake.  By exporting metabolites back into hepatic blood 
through MRP3 to allow for downstream reuptake through OATPs, the liver maintains a salvage 
pathway by which it can circumvent the retention of potentially toxic compounds or their 
metabolites in the event of saturated excretion processes in upstream hepatocytes(Iusuf, Steeg, 
& Schinkel, 2012).   
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Figure 1.7. Hepatocyte hopping and recirculation of SG.  After oral administration, sorafenib enters the 
hepatocytes by incompletely defined transporters mechanisms, including OATP1B-type carriers and OCT1, and 
undergoes CYP3A4-mediated metabolism to sorafenib-N-oxide (s-N-oxide) and conjugation by UGT1A9 to form SG. 
After conjugation, SG is extensively secreted into the bile by a process that is mainly mediated by ABCC2. Under 
physiologic conditions, a fraction of the intracellular SG is secreted by ABCC3 and at least one other transporter back 
to the blood, from where it can be taken up again into downstream hepatocytes via OATP1B1-type carriers (Oatp1a 
and Oatp1b in mice). This secretion-and-reuptake loop may prevent the saturation of ABCC2-mediated biliary 
excretion in the upstream hepatocytes, thereby ensuring efficient biliary elimination and hepatocyte detoxification. 
Once secreted into bile, SG enters the intestinal lumen where it serves as a substrate for as yet unknown bacterial β-
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glucuronidases (βGLU) that produce sorafenib, which subsequently undergoes intestinal absorption and reenters the 
systemic circulation.  Vasilyeva et al., Therapeutics, Targets, and Chemical Biology, 2015, 75.13, 2729-2736. 
Previous studies by the Schinkel group have found that OATP1B1/1B3, MRP3, and 
MRP2 function play significant roles in hepatocyte hopping.  The plasma concentrations of 
bilirubin, a heme degradation product, drastically increases in Oatp1a/1b cluster knockout mice, 
mostly through an increase in its metabolite, bilirubin-monoglucuronide (BMG).  This increase is 
reversed, however, in combination Oatp1a/1b cluster and Abcc3 knockout mice, indicating that 
the plasma accumulation was due to Mrp3 efflux of the metabolite and that Oatp transporters 
and Mrp3 form a hepatocellular shuttling route for bilirubin(Iusuf et al., 2012).  It was also 
determined in later studies that sorafenib-glucuronide followed the same hepatocellular shuttling 
loop, and it is likely that a number of substrates would be impacted by the hepatocyte hopping 
pathway(Vasilyeva et al., 2015) (fig.1.6).  As hepatocyte hopping relies on transporter function 
to shuttle compounds to downstream hepatocytes, liver conditions such as NASH that cause 
drastic alterations to ADME processes would be detrimental to this pathway, and disruption of 
normal hepatocellular shuttling could be the underlying mechanism behind the altered 
pharmacokinetics seen in NASH. 
Hepatocyte hopping as an underlying mechanism of pharmacokinetic alteration in NASH 
is supported by changes to drug disposition observed in both human and rodent models of 
disease.  The three mechanisms involved in hepatocyte hopping are correspondingly regulated 
in both the human disease and MCD-diet induced NASH, as has been shown with both 
APAP/APAP-glucuronide and morphine.  In the case of APAP and APAP-glucuronide, the biliary 
concentrations of APAP and its metabolites were significantly decreased in NASH, while the 
Mrp3 substrate APAP-glucuronide was elevated in NASH rat plasma and urine when compared 
to the other metabolites(Lickteig et al., 2007).  This pattern was also identical to the one found in 
human patients dosed with APAP(Canet et al., 2015), indicating that the changes to the 
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MRP2/MRP3 axis are the same between the MCD diet and human NASH.   Similarly, the 
changes to morphine pharmacokinetics follow the same trend in the MCD rat model and human 
patients, showing an increase in systemic morphine-glucuronide exposure, and an increase in 
serum exposure of M3G due to decreased biliary efflux and increased sinusoidal efflux of the 
metabolite(A. L. Dzierlenga et al., 2015; Ferslew et al., 2015; Pierre, Johnston, Ferslew, 
Brouwer, & Gonzalez, 2017).  Alterations to OATP uptake transporters are also known to be 
concordant between the MCD diet and human NASH(Clarke et al., 2014).  As NASH is known 
to disrupt the three cooperative transport mechanisms involved in hepatocyte hopping, this 
forms the basis for a potential underlying mechanism for altered drug disposition in human 
NASH patients. 
Hepatic Iron Regulation and NASH 
Iron is regulated in the liver in multiple ways, but one of the major methods of controlling 
iron levels is through iron transport proteins. Ferroportin, a transmembrane protein found in 
various cell types, including hepatocytes and enterocytes, functions to move iron from the inside 
of a cell to the bloodstream. As the only known mammalian iron exporter, ferroportin plays a key 
role in the retention of iron, and dysregulation of the transporter can be the root cause of iron 
accumulation(D. Chen et al., 2007; Ward & Kaplan, 2012). The hormone hepcidin is the main 
regulator of ferroportin function, and therefore is one of the principal regulators of iron 
metabolism as a whole. Hepcidin regulates ferroportin activity by binding to its active site and 
catalyzing its internalization, removing it from the membrane(Bogdan, Miyazawa, Hashimoto, & 
Tsuji, 2016; Nemeth & Ganz, 2006), and is itself regulated by intracellular iron concentrations 
and Nrf2(Silva-Gomes et al., 2014; Tanaka, Ikeda, Yamamoto, Ogawa, & Kamisako, 2012). 
Iron homeostasis is particularly important in humans, as iron cannot be excreted from 
the body by any means other than hemorrhaging or enterocyte sloughing(Nemeth & Ganz, 
2006). Under normal conditions, iron levels are strictly maintained to prevent the deleterious 
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effects of overload or deficiency; however, conditions like liver disease have been known to 
disrupt iron homeostasis through dysregulation of hepcidin(Bekri et al., 2006; Nemeth et al., 
2004). In iron overloaded mice, hepcidin mRNA and protein expression is significantly 
upregulated, reducing intestinal iron uptake but also preventing iron release from hepatocytes. 
Concordant results are found with multiple models of iron overload in rodents, indicating that the 
increase in hepcidin could be attributed to iron accumulation and not to other factors(Pigeon et 
al., 2001). In humans, hepcidin levels are correlated with hepatic iron accumulation and 
hemoglobin, as well as decreased liver function. Hepcidin is also significantly upregulated 
during inflammation, and can rise to levels far higher than what is seen for normal iron 
regulatory function(Nemeth & Ganz, 2006). In patients with NAFLD and NASH, serum hepcidin 
levels are positively associated with increased triglycerides, cholesterol, and inflammation, and 
worsened NAS scores(Senates et al., 2011; Zimmermann et al., 2011). Elevated triglyceride 
and cholesterol levels and inflammation are all well-known hallmarks of NASH; this association 
suggests the possibility of iron accumulation via the inability to remove iron from hepatocytes, 
and thus indicates a potential link between hepcidin levels, iron accumulation, and hepatic 
injury. 
Transferrin receptor-1 (TfR1) is a ubiquitously expressed iron uptake protein that imports 
iron into cells. It facilitates the transport of the glycoprotein transferrin, which contains two high-
affinity Fe(III) binding sites and modulates the amount of free iron in blood. In addition to TfR1, 
TfR2 is a homolog of TfR1 that is located in specific tissues like hepatocytes and hematopoietic 
cells, and can also internalize diferric-transferrin.  The exact function of TfR2 is not fully known, 
but it is postulated that it acts in a regulatory fashion, whereas TfR1 is the main transporter for 
iron uptake(Goswami & Andrews, 2006). TfR1 is controlled post-transcriptionally by intracellular 
iron levels through the interaction of iron response proteins (IRP1/2) and the iron response 
element (IRE) on mRNA.  TfR1 is the only known protein to contain multiple IRE hairpins; it has 
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5 of these motifs located in its 3’ UTR, and binding of the IRPs to these motifs stabilizes the 
mRNA and allows for translation(PANTOPOULOS, 2004). Regulation of IRP1 comes through 
post-translational alterations in structure in response to the presence or absence of iron.  IRP1 
contains an iron-sulfur cluster that acts as a kind of ‘switch’ in the presence of iron, changing the 
protein to a cubane structure that prevents it from binding to mRNA(Haile et al., 1992; 
PANTOPOULOS, 2004). However, IRP1 is not solely modulated by iron, as it has also been 
shown to become rapidly activated in the presence of ROS and capable of binding to 
IRE(Mueller, Pantopoulos, Hübner, Stremmel, & Hentze, 2001; Pantopoulos & Hentze, 1998). 
IRP2 is homologous to IRP1, except for a unique 73 amino acid iron-dependent ‘degradation 
domain’; this domain contains 3 critical cysteine residues that, when oxidized by iron, allow for 
recognition of the protein by proteasomes and rapid degradation, and is the main means of 
regulating the protein(Iwai, Klausner, & Rouault, 1995; PANTOPOULOS, 2004). 
The ROS produced by iron accumulation may also have an effect on ferritin, the main 
intracellular protein for the cellular storage of iron. Ferritin is a globular protein composed of 24 
subunits of either heavy or light isoforms, and is responsible for containing iron in a soluble and 
nontoxic form(ten Kate, Wolthuis, Westerhuis, & van Deursen, 1997). Ferritin production is 
mediated post-translationally by a mechanism similar to TfR1, but in a negative fashion. While 
the binding of IRPs to the IRE sites on TfR1 stabilizes the protein, the binding of IRP to the 
single IRE motif in the 5’ UTR of ferritin mRNA inhibits its translation(PANTOPOULOS, 2004). 
Different cell types also produce ferritin with different heavy to light subunit ratios; the liver and 
spleen contain ferritin with higher proportions of light subunits. The isoforms of the ferritin 
subunits are particularly important, as the heavy subunits have ferroxidase activity to convert 
iron from the ferrous to the more stable ferric form for storage. When antioxidants are depleted, 
as in conditions of high oxidative stress, ferroxidase activity becomes downregulated, 
preventing the removal of ferrous iron from iron pools in the cell. Additionally, a rapid release of 
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iron from ferritin occurs during these conditions due to increasing reducing potential and 
anaerobiosis.(Manuel Fernandez-Real, Lopez-Bermejo, & Ricart, 2002)  Overall, this results in a 
decrease in ferric iron within ferritin proteins and an increase in ferrous iron in intracellular iron 
pools, with a greater abundance of iron available for deleterious ROS generation. 
The deleterious effects of iron accumulation is well understood and has significant 
support from the literature; the liver’s role as the main organ for iron metabolism, the incidence 
of hepatic iron accumulation in fatty liver diseases, the beneficial effects of iron removal seen in 
chronic liver disease patients and the effects of ROS and chronic liver diseases on iron storage 
mechanisms suggests that iron plays an exacerbating role in disease progression. 
Current Study 
The alterations to pharmacokinetics that occur due to genetic polymorphisms of DMEs 
and hepatic transporters and the progression of NASH has been well documented in various 
studies; the interaction of genetic variants with the alterations that occur during NASH, however, 
has not been greatly explored.  As NASH is rapidly becoming one of the most prevalent chronic 
liver diseases and polymorphisms of DMEs and hepatic transporter proteins are relatively 
common in human populations, it has become increasingly likely that patients with some form of 
genetic variation in a key ADME gene will present with NASH.  Previous research with a rodent 
model of NASH and pravastatin has indicated that there can be synergistic relationships 
between genetic polymorphisms of xenobiotic transporters and NASH, resulting in dramatic 
increases in plasma and tissue concentrations and an increased risk of toxicity(Clarke et al., 
2014).  Though full genetic knockout resulted in significantly increased plasma and tissue 
retention of the compound, the question still remained as to whether full disruption was 
necessary to observe this change, or whether the accumulation would be affected by gene 
dose.  Additionally, while that particular study focused on the genetic loss of Oatp1b2/OATP1B1 
and NASH on the disposition of statins, other transporter proteins also significantly impact drug 
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disposition, and thus the combination of polymorphisms of these critical transporters and 
chronic disease may result in increased risk of toxicity.  Polymorphisms of BCRP, an efflux 
transporter located on the bile canaliculus, have been implicated in altered pharmacokinetics 
sunitinib, imatinib, and other chemotherapeutics; pharmacokinetic changes have also been 
found with polymorphisms of MRP2 for docetaxel, mycophenolic acid, lumefantrine, and 
pravastatin(Patel, Taskar, & Zamek‐Gliszczynski, 2016; Terada & Hira, 2015; Vos et al., 2017).  
As NASH results in the dysregulation of other compensatory transporter pathways, the 
interaction between the disease and polymorphisms of hepatic efflux transporters may result in 
pharmacokinetic changes that are greater than the sum of their parts, and identifying these 
synergistic interactions is important to precision medicine.  Additionally, it would be important to 
determine the underlying mechanism by which the interplay of hepatic uptake and efflux 
transporter alteration causes the pharmacokinetic changes observed in NASH.    
Given these research questions, the purpose of this study was to identify the impact of 
gene-by-environment interactions of hepatic xenobiotic transporter polymorphisms and 
nonalcoholic steatohepatitis on drug disposition and toxicity via the studies described in the 
following aims: 
Aim 1 (Chapter 2):  Determine the gene-by-environment interaction of hepatic efflux transporter 
polymorphisms and NASH using probe substrates of Bcrp and Mrp2.  
Using Bcrp knockout and wild-type rats and the probe substrates SN-38 and SN-38-
glucuronide, this study identified the interaction of deleterious Bcrp polymorphisms and NASH 
on drug disposition.  These data were valuable in determining the synergistic interaction of 
hepatic efflux transporter polymorphisms and NASH on pharmacokinetics. 
Aim 2 (Chapter 3):  Determine the impact of hepatic uptake transporter gene dose and NASH 
on drug disposition using a probe substrate of Oatp1b2. 
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Using Oatp1b2 heterozygous, knockout, and wild-type mice with the probe substrate 
pravastatin, this study identified the impact of hepatic uptake transporter gene dose and NASH 
on drug disposition.  These data were necessary for determining the extent of genetic disruption 
to hepatic uptake transporters that is required to observe a synergistic gene-by-environment 
interaction. 
Aim 3 (Chapter 4):  Determine the impact of hepatic xenobiotic transporter alteration during 
NASH on hepatocyte hopping. 
Using Oatp1a/1b cluster knockout, Mrp2 knockout, and wild-type mice with the probe 
substrate sorafenib-glucuronide, this study described the process of hepatocyte hopping in a 
rodent model of NASH, which pinpointed the underlying mechanism of pharmacokinetic 
alteration in NASH.   
Aim 4 (Chapter 5):  Identify the alterations to iron regulatory proteins, iron transporters, and iron 
storage during NASH. 
Using human and MCD diet-induced NASH rat liver tissue, this study investigated the 
alterations to hepatic iron storage in hepatocytes via histological iron staining with Perls’ 
Prussian blue, as well as the changes in the mRNA and protein expression of key mediators of 
iron regulation. 
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CHAPTER TWO: GENE-BY-ENVIRONMENT INTERACTION OF BCRP−/− AND 
METHIONINE- AND CHOLINE-DEFICIENT DIET–INDUCED NONALCOHOLIC 
STEATOHEPATITIS ALTERS SN-38 DISPOSITION 
 
Toth EL, Hui L, Dzierlenga AL, Clarke JD, Vildhede A, Goedken M, Cherrington NJ 
Published in Drug Metab. Disp. 
Introduction  
Adverse drug reactions (ADRs) are becoming increasingly frequent, and approximately 1 
in 20 hospital patients experience an ADR in the United States (Bourgeois et al., 2010; 
Stausberg, 2014).  Variations in drug response can occur due to a variety of factors, including 
alterations to drug metabolizing enzymes and transporters. Understanding the mechanistic 
basis behind inter-individual variability can potentially identify at-risk populations. 
Many variations in drug response can be attributed to genetic polymorphisms in genes 
that are responsible for the absorption, distribution, metabolism, and excretion (ADME) 
processes that determine the pharmacokinetics of drugs.  Single nucleotide polymorphisms 
(SNPs) in SLCO1B1 have been linked to increases in statin plasma concentrations as well as 
increases in statin-induced myopathy(Yee et al., 2018).  Variations in multidrug resistance 
proteins have been known to influence therapeutic outcomes of anti-cancer treatments such as 
difluomotecan(Sparreboom et al., 2004) and doxorubicin(Lal et al., 2008).  Genetic variations, 
however, are not the sole factor involved in variable response; alterations in response to 
disease pathogenesis may also affect ADME processes and contribute significantly to ADRs.  
Transient alterations in transporter function due to disease can alter drug disposition in a 
manner that closely resembles the loss of function due to genetic variations.  These alterations 
create a phenotype that is incongruent with genotype; a phenomenon referred to as 
phenoconversion.   
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Nonalcoholic steatohepatitis (NASH) is the hepatic manifestation of metabolic syndrome. 
Disease progression to NASH presents with hepatocellular injury, inflammation, and fibrosis 
(Marra et al., 2008) and the prevalence of NASH is overall about 1.5-6.45%(Sayiner, Koenig, 
Henry, & Younossi, 2016b).  In addition to the histological changes, there are also significant 
alterations to hepatic enzyme and transporter mRNA, protein expression, and function that are 
important to ADME processes, such as the ATP-binding cassette transporter (ABC) family 
(Anika L Dzierlenga et al., 2016; R. N. Hardwick et al., 2013).  A global transcriptional study 
among NASH patients showed that the effect of NASH progression on transporters is a 
phenoconversion event; many uptake transporters are significantly downregulated, and efflux 
transporters like MRP2, MRP3, and BCRP are significantly upregulated (Lake et al., 2011).  
Both MRP2 and BCRP are members of the ABC family and are located on the bile canaliculus 
of the liver, where they efflux endo- and xenobiotics.  MRP3 is an ABC transporter located on 
the sinusoidal membrane, where it transports compounds back into the blood.  Mislocalization of 
MRP2 during NASH significantly decreases its function (A. L. Dzierlenga, Clarke, & Cherrington, 
2016), and alterations to the MRP2/MRP3 transport system can result in significantly altered 
drug disposition such as the increase in plasma retention of pemetrexed in rodent models of 
NASH (Anika L Dzierlenga et al., 2016).  mRNA analyses of human NASH liver tissue have also 
shown an increase in BCRP expression during the disease (R. N. Hardwick et al., 2011). 
Alterations in BCRP function have not been explored, and it is important to understand changes 
to BCRP in the context of other transporters. 
Irinotecan is a camptothecin-derivative chemotherapeutic that is used to treat colorectal 
cancers, the third leading cause of cancer death (Siegel, Desantis, & Jemal, 2014).  It 
undergoes hepatic metabolism to a variety of metabolites, only one of which, SN-38, is active.  
SN-38 is a known substrate of BCRP (Houghton et al., 2004; Tuy et al., 2016), and SN-38G, like 
many glucuronides, is thought to be mainly exported through MRP2(Kroetz, 2006).  Patient 
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response to irinotecan, however, is highly variable and carries a significant risk of life-
threatening side effects (Falcone et al., 2007).  Enzyme polymorphisms, such as UGT1A1*28, 
account for only a portion of this variability (Sadée & Dai, 2005).   Hepatobiliary efflux of SN-38 
and SN-38G facilitates the toxic effects in the intestine (Kato, Suzuki, & Sugiyama, 2002). 
Additionally, SN-38G in the intestine is converted back into SN-38 by β-glucuronidase and is 
then reabsorbed into systemic circulation, which is vital to irinotecan therapy as it prolongs 
circulation time (Hasegawa et al., 2006). Given the previous data on the effects of NASH on 
hepatobiliary transport of xenobiotics, it was hypothesized that functional alterations of BCRP 
and MRP2 during NASH would alter the disposition of SN-38 and SN-38G, potentially 
contributing to variable response.  It was postulated that alterations to BCRP during NASH 
would significantly alter biliary elimination of SN-38 and lead to decreased plasma 
concentrations; it was similarly proposed that mislocalization of MRP2 could significantly reduce 
biliary elimination of its substrate, SN-38G, and lead to plasma accumulation.  This study aimed 
to determine the effect of Bcrp polymorphic loss of function and NASH alone, and in a gene-by-
environment interaction, on the disposition of SN-38 and SN-38G.  The observations made 
through comparison of these models may provide mechanistic insight into inter-individual 
variability, and a basis for response prediction in human NASH patients. 
Materials and Methods 
Reagents  
SN-38 and camptothecin were purchased from Sigma-Aldrich (St. Louis, MO), and SN-
38-glucuronide was purchased from Toronto Research Chemicals (Toronto, Ontario, Canada).  
Urethane, UPLC–grade acetonitrile, and UPLC-grade water were obtained from Sigma-Aldrich.   
Heparin was purchased from Alfa Aesar (Ward Hill, MA).  ReadyScript® cDNA synthesis kit, 
KiCqStart™ SYBR® green qPCR with low ROX™ master mix, and PCR primers for Bcrp and β-
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actin (Actb) were obtained from Sigma-Aldrich.  RNA Bee isolation reagent was obtained from 
Amsbio (Cambridge, MA).   
Animals  
Male Bcrp knockout and wild-type Sprague-Dawley rats of at least 8 weeks of age were 
purchased from Horizon Discovery (Saint Louis, MO). Animals were housed in a University of 
Arizona Association for Assessment and Accreditation of Laboratory Animal Care–certified 
animal facility with a 12-hour light-dark cycle and allowed to acclimatize for at least one week 
before experiments.  A methionine and choline deficient diet (MCD) or control diet from Dyets, 
Inc (Bethlehem, PA) was given ad libitum for 8 weeks when the animals were 16 weeks of age.  
After 8 weeks of diet, the animals underwent disposition studies. All handling, maintenance, 
care, and testing of the animals was in accordance with NIH policy, and experimental protocols 
were approved by the University of Arizona Institutional Animal Care and Use Committee. 
SN-38 and SN-38G Disposition Studies  
A stock solution of 10 mg/mL of SN-38 was prepared in DMSO.  From this stock 
solution, a 0.8 mg/mL SN-38 co-solvent solution was prepared for injection.  This solution was 
made by adding the SN-38 stock solution to a solution of ethanol, propylene glycol and Tween-
80, then diluting in water.  The final proportion of each component was as follows: 14% ethanol, 
40% propylene glycol, 3% Tween-80, 10% DMSO and 33% water.  No more than 5 mL/kg of 
solution was administered. 
Animals were anesthetized for cannulation surgery using an intraperitoneal bolus dose 
of urethane (1g/kg, up to 10 mL/kg in saline).  In order to assess the disposition of SN-38 and 
SN-38G, cannulas were inserted into the jugular vein for drug and saline administration, carotid 
artery for blood collection, and bile duct for bile collection.  Prior to dosing, blood was collected 
from the arterial cannula as a baseline.  A bolus dose of 0.8mg/kg SN-38 was then administered 
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intravenously over a period of 90 seconds.  After drug administration, blood was collected at 2, 
7, 12, 20, and 40 minutes, while bile was collected at 0, 15, 30, and 45 minutes.  Terminal liver 
and kidney was collected at 90 minutes.  A portion of collected tissue was prepared for 
histological analyses by fixing in 10% neutral-buffered formalin for 24 hours, then exchanging 
for 70% ethanol until embedded in paraffin by the University of Arizona Histology Service 
Laboratory. The remaining tissue was flash-frozen in liquid nitrogen for storage at -80oC.  Blood 
was collected in heparin-coated microcentrifuge tubes and was spun down for 10 minutes at 
10,000xg to separate plasma from blood cells. Plasma and bile samples were also stored at -
80oC. 
SN-38 and SN-38G Quantification 
Sample clean-up for blood and bile samples was performed using the Bond Elut 96 
Plexa solid-phase extraction plates (Agilent, Santa Clara, CA) according to the manufacturer’s 
protocol.  40μL of plasma and 10μL of bile were used in the sample preparation process.  The 
eluent was then evaporated to dryness and reconstituted in 120 uL of mobile phase for injection 
onto the LC-MS/MS.  The tissue homogenates were made from 300mg of tissue and then 
cleaned up via protein precipitation in a 1:3 solution of homogenate to UPLC-grade acetonitrile.  
The samples were vortexed and kept on ice for 10 minutes, then centrifuged at 13,000 rpm for 
10 minutes.  The supernatant was collected in a new microcentrifuge tube and evaporated to 
dryness.  The sample was reconstituted in 120 uL of mobile phase, centrifuged at 10,000 rpm 
for 5 minutes, and the supernatant was collected for injection onto the LC-MS/MS, as previously 
described(Khan et al., 2005). 
The method for quantification of SN-38 and SN-38G in plasma, bile, and tissue was 
adapted from previously published methods(D’Esposito, Tattam, Ramzan, & Murray, 2008; 
Khan et al., 2005).   The Arizona Laboratory for Emerging Contaminants at the University of 
Arizona provided a Waters (Milford, MA) Micromass Quattro Premier XE tandem mass 
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spectrometer coupled to an Acquity UPLC. The mobile phase consisted of a gradient of water 
(solvent A) and acetonitrile (solvent B) with 0.1% formic acid at a flow rate of 0.3mL/min through 
a Waters Acquity UPLC BEH C19 column (1.7 μm, 2.1 × 50 mm).  The mobile phase was 
composed of A:B 90:10 (v:v) running to A:B 10:90 (v:v) over 1.0-6.0 minutes, then returned to 
A:B 90:10 over 60 seconds with two minutes of equilibration, for a total run time of 9.0 minutes.  
Multiple reaction monitoring in positive mode was used to detect SN-38 at m/z 393>349, SN-
38G at m/z 569.0>393.2 and camptothecin at m/z 349.1>305.2. The retention times for SN-38, 
SN-38G, and camptothecin were 3.6 minutes, 3.1 minutes, and 3.8 minutes, respectively.  
Recovery determination was done using four replicates, and the recovery in plasma and bile 
respectively were: 76.3% and 86.8% for SN-38, 81.3% and 77.4% for SN-38G, and 80.6% and 
81.8% for internal standard.  The linear range of SN-38 and SN-38G in plasma was from 
50ng/mL to 1000 ng/mL, and the range in bile was from 50ng/mL to 5μg/mL.  The lower limit of 
quantification (LLOQ) in plasma was found to be 15ng/mL for SN-38 and 20ng/mL for SN-38G; 
in bile, it was found to be 20ng/mL for both SN-38 and SN-38G. Peak analysis was done in 
MassLynx Mass Spectrometry software and data analysis and processing was done using 
GraphPad Prism 5.0. 
Quantitative Reverse Transcription-PCR   
RNA was isolated from liver tissue using the RNA Bee isolation reagent.  Between 200-
300 mg of tissue was added to 4 mL of RNA Bee and homogenized.  The manufacturer’s 
protocol was followed and the resulting RNA pellet was reconstituted in 250uL of DEPC water 
per 100 mg of tissue, then was stored at -80oC.  RNA concentration was determined using a 
NanoDrop 2000 UV-visible spectrophotometer (Thermo Fisher Scientific).  Final preparations of 
RNA had a 260/280 quality ratio between 1.6 and 1.9.  cDNA was prepared from the isolated 
RNA using the ReadyScript® cDNA synthesis kit from Sigma-Aldrich.  Each reaction well 
contained 1x KiCqStart™ SYBR® green master mix, 100nM of forward and reverse primers, 
53 
 
2µL of cDNA template, and nuclease-free water up to 20µL, run in duplicate.  Reactions were 
run on an ABI StepOnePlus Real Time PCR system with the standard SYBR® green PCR 
cycling profile.  Fold change was determined using the delta-delta CT method. 
Histopathology   
          Paraffin-embedded liver sections were stained with hematoxylin and eosin then examined 
by a board-certified veterinary pathologist. Tissues were incidence and severity scored using an 
established rodent NASH system (Kleiner et al., 2005) with endpoints including steatosis, 
necrosis, inflammation, hyperplasia and biliary hyperplasia. Representative digital images were 
acquired.  Rank-order statistical methods and one-way ANOVA were used to determine 
differences between groups. 
IHC   
Immunohistochemistry staining was performed on formalin-fixed paraffin-embedded 
tissue slides.  The slides were deparaffinized in 100% xylene and hydrated in 100% ethanol.  
Antigen retrieval was performed in boiling pH 9.0 Tris-EDTA.  Endogenous peroxidases were 
blocked using 0.3% (v/v) H2O2 in phosphate buffered saline (PBS) for 20 minutes.  MRP2 was 
stained by incubating the slides overnight at 4oC with anti-MRP2 antibody (Sigma-Aldrich, 
M8163), followed by the Mach 4™ staining kit protocol (Biocare Medical).  Images were taken 
using a Leica DM4000B microscope with a DFC450 camera. 
Protein Preparation   
Crude membrane fractions were obtained from liver samples.  Approximately 500mg of 
tissue was homogenized in 5mL of cold ST buffer (Sucrose Tris buffer, 10mM tris base and 
250mM sucrose with 1 Protease Inhibitor Cocktail tablet (Roche, Indianapolis, IN) per 25 ml, pH 
7.5).  Homogenates were centrifuged at 10,000xg for 20 minutes to remove nuclei; the 
supernatant was decanted into a second set of ultracentrifuge tubes.  The supernatant was 
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spun at 100,000xg for 60 minutes to pellet the membranes.  Membrane pellets were rinsed with 
buffer before being resuspended in 200µL of buffer and stored at -80oC.  Protein concentrations 
were determined by BCA assay (Thermo Fisher Scientific). 
Immunoblotting  
Immunoblotting for MRP2 and MRP3 was performed using crude membrane 
preparations.  Membrane preparations (60µg/lane) were separated by SDS-Page on 7.5% 
polyacrylamide gels.  The proteins were transferred to polyvinylidene difluoride membranes, and 
then blocked with 5% nonfat dry milk in Tris-buffered saline/Tween-20 for at least one hour.  
The membranes were probed with MRP2 (Sigma-Aldrich, M8163) or MRP3 (Santa Cruz 
Biotechnology, SC-5775) primary antibody at a dilution of 1:500 in 2.5% blocking solution.  
Image processing and analysis through the ImageJ software (National Institutes of Health, 
Bethesda, MD) determined relative protein density and the proteins were normalized to the 
housekeeping protein ERK2 (Santa Cruz Biotechnology, SC-125).  
Targeted Proteomic Quantitation of Bcrp Surrogate Peptide   
Homogenization of liver tissues was done in a FastPrep 24 bead mill homogenizer (MP 
Biomedicals, Santa Ana, CA) with 1.4 mm ceramic beads.  The ProteoExtract™ Native 
Membrane protein extraction kit (EMD Millipore, Billerica, MA) was used to prepare membrane 
fractions according to the manufacturer's protocol, and protein concentrations were 
subsequently determined by BCAassay (Pierce, Rockford, IL).  300 μg aliquots of membrane 
protein fraction were prepared in 100 mM ammonium bicarbonate with 3.7 w/v% sodium 
deoxycholate, and then were reduced using 6 mM dithiothreitol (DTT) for 5 minutes at 95oC.  
The samples were alkylated with 15 mM iodoacetamide for 20 minutes at room temperature, 
protected from light.  Matrix for calibration curves was obtained from human serum albumin 
processed under the same conditions.  Protein digestion was performed over 24 hours at 37oC 
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with a protein:trypsin ratio of 1:20.  The reaction was quenched with 0.2% formic acid.  Bcrp 
peptide labeled with a stable isotope (SIL) was added as internal standard to each sample post 
digestion and unlabeled peptide standard was added into the matrix samples in known 
concentrations.  The acid-precipitated sodium deoxycholate was pelleted out of the samples by 
centrifugation at 16,000xg and 4oC. The supernatant was transferred to a LoBind plate 
(Eppendorf, Hamburg, Germany) and evaporated under nitrogen to concentrate, then 
reconstituted in 0.1% formic acid for injection onto the LC-MS/MS. 
Peptide quantification was performed on an API-6500 triple quadrupole mass 
spectrometer operating in ESI mode with a Shimadzu LC-30AD interface.  The mobile phase 
consisted of solution A, 0.1% FA in water and solution B, 0.1% FA in 90:10 acetonitrile:water set 
to a flow rate of 0.2 mL/min.  10 μL of sample was injected onto a Kinetex C18 core-shell 
column (1.7 μM, 100Å, 100 x 2.1 mm), and separation occurred along the following solvent 
gradient: 5.5% mobile phase B for 5 minutes, linear gradient of 5.5 to 33.3% mobile phase B 
over 40 minutes, hold at 33.3% for 5 minutes, wash at 100% mobile phase B for 5 minutes, then 
re-equilibration for 4 minutes.  Multiple reaction monitoring was used to detect the analyte 
peptide (SSLLDVLAAR) at transition 523.1>757.5 and the SIL peptide at 528.1>767.5.  The 
mass spectrometer settings were: 500oC source temperature, 5 kV ion spray voltage, 10eV 
entrance potential, 50 V declustering potential, 25 V collision energy, and 15 V collision cell exit 
potential.  Data were processed in Analyst 1.6.2 (SCIEX, Ontario, Canada) and the external 
peptide calibration curve was used to determine BCRP peptide concentration in the samples. 
Statistical Analyses 
All results are represented as the mean ± standard deviation (SD).  Two-way ANOVA 
statistical analyses with Bonferroni post-test were used to compare between control and NASH 
animals of each genotype group.  Each group consisted of n=3 animals, except for KO-MCD 
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group, which consisted of n=4. 
Results 
Effects of MCD Diet-Induced NASH on the Disposition of SN-38 and SN-38G 
Hemotoxylin- and eosin-stained liver sections were examined under a light microscope at 40x 
magnification for histological analysis (Fig. 2.1).   
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NASH hallmarks were observed in rats fed an MCD diet for 8 weeks, including steatosis, 
inflammation, necrosis, fibrosis, and biliary hyperplasia.  This is consistent with previous 
observations using an established NASH scoring system and recapitulates the histological 
Figure 2.1. Liver histopathology of control and MCD-diet rats. Hemotoxylin and eosin stained liver sections of control 
rats and rats fed 8 weeks of MCD diet, wild-type and Bcrp knockouts. Hallmark characteristics of NASH were found in 
MCD rats, while control group animals showed no signs of NASH pathology. Original magnification, 40x. 2-way 
ANOVA,*P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, n=3, n=4 (KO-MCD) . 
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findings in human disease(Canet et al., 2014; Kleiner et al., 2005).  There was no significant 
interaction between the genetic knockout and disease in the severity of NASH hallmarks, except 
for fibrosis; in KO-MCD animals, fibrosis was more severe than in KO-C animals.  The effects of 
NASH on SN-38 and SN-38G disposition were observed over 90 minutes.  The plasma AUC of 
SN-38 and SN-38G showed no significant alterations between MCD groups and their controls 
(Fig 2.2). 
 
 
Significant reductions in biliary efflux were seen for SN-38 and SN-38G between the KO-C and 
KO-MCD groups (Fig 2.3 A and B).   
Figure 2.2. Effects of MCD diet on systemic exposure of SN-38 and SN-38G. Plasma concentrations 
were taken over 40 minutes after intravenous infusion of 0.8mg/kg SN-38. Graphs represent mean ± S.D., 
n=3, n=4 (KO-MCD) 
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Biliary efflux of SN-38 in the KO-MCD group decreased to 31.9% of control (from 5.59± 
0.102µg/min to 1.79±0.058µg/min), and efflux of SN-38G decreased to 38.7% of control (from 
49.18±0.944µg/min to 19.15±2.04μg/min).  
The hepatic and renal tissue concentrations of SN-38 and SN-38G showed high variability and 
no statistically significant differences between the MCD groups and their controls (Fig. 2.3 C).   
Effects of MCD Diet-Induced NASH on Mrp2 and Mrp3 Protein Expression 
Figure 2.3. Effects of MCD diet on biliary excretion of SN-38 and SN-38G. Bile concentrations were taken 
over 45 minutes after intravenous infusion of 0.8mg/kg SN-38. Graphs represent mean ± S.D. 2-way 
ANOVA,*P ≤ 0.05, n=3, n=4 (KO-MCD) . 
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Relative protein concentrations of MRP2 and MRP3 and localization of MRP2 were 
determined by Western blotting and immunohistochemistry (IHC), respectively.  Densitometric 
analysis was used to compare relative protein expression between groups (Fig. 2.4).   
 
 
MRP3 increased by 10-fold in the WT-MCD group when compared to control, and increased by 
3.5-fold in the KO-MCD group when compared to control.  Protein concentrations of MRP2 
remained relatively unchanged between the WT-C and WT-MCD groups and the KO-C and KO-
MCD groups.  Immunohistochemical staining of MRP2 revealed normal localization at the 
canalicular membrane in the control groups, while MCD groups showed pockets of internalized 
Figure 2.4. Alterations of Mrp2 and Mrp3 protein expression in MCD diet. Relative protein expression of (A) Mrp2 
and (B) Mrp3 between control and MCD groups. (C) Relative protein expression was determined by immunoblot 
analysis. Graphs represent mean ± S.D. 2-way ANOVA,*P ≤ 0.05, n=3, n=4 (KO-MCD) 
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staining, indicating mislocalization consistent with previous observations(A. L. Dzierlenga et al., 
2015; Anika L Dzierlenga et al., 2016) (Fig 2.5). 
 
   
Effects of MCD Diet-Induced NASH on Bcrp Expression 
 mRNA expression of Bcrp was determined by qRT-PCR and relative protein 
concentration was determined by LC-MS/MS analysis of BCRP surrogate peptide (Fig. 2.6).   
Figure 2.5. Mislocalization of Mrp2 in MCD diet. Protein localization of Mrp2 was visualized by 
immunohistochemistry in paraffin-embedded liver tissue of controls and MCD groups. Representative 
images were taken at 100x magnification. 
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Bcrp mRNA increased by two-fold in the WT-MCD group when compared to its control, while 
both knockout groups showed no expression.  Protein expression of BCRP increased in keeping 
with mRNA expression, showing a 1.6-fold increase in the MCD group when compared to 
controls, and no expression in the knockout groups. 
Discussion  
Figure 2.6. Alterations of Bcrp protein and mRNA expression during MCD diet. (A) mRNA expression was determined 
by qRT-PCR analysis and fold change was determined using the delta-delta CT method. Protein expression was 
determined by proteomic analysis using LC-MS/MS. Graphs represent mean ± S.D. 2-way ANOVA, *P ≤ 0.05 and ***P≤ 
0.01., n=3, n=4 (KO-MCD). (B) Representative chromatograms of WT-C, WT-MCD, and KO groups. Left chromatogram 
depicts native protein concentration and right chromatogram depicts internal standard peptide. 
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The hepatobiliary disposition of SN-38 and SN-38G is mediated by BCRP and MRP2 
transport, and during NASH, alterations to BCRP function can significantly impact systemic drug 
exposure. It has been previously established that alterations of hepatobiliary efflux pathways 
can affect the distribution of xenobiotics in bile and plasma, potentially increasing patient 
exposure and the risk of toxicity.  The MRP2/MRP3 hepatobiliary efflux pathway has been found 
to play a significant role in the distribution of various xenobiotics, including the 
chemotherapeutics pemetrexed and methotrexate, and analgesics like morphine(A. L. 
Dzierlenga et al., 2015; Anika L Dzierlenga et al., 2016; Ferslew et al., 2015; R. Hardwick et al., 
2014).  The participation of other transport proteins can also affect the distribution and toxicity of 
xenobiotics.  Uptake transporters contribute significantly to the uptake and clearance of various 
drugs, including SN-38.  In human patients, the hepatic uptake of 99mTc‐mebrofenin (MEB), a 
substrate for OATP1B1 and OATP1B3, was significantly decreased in NASH due to disease-
related impairment(I. Ali et al., 2017). Oatp1a/1b-/- mice exhibit increased SN-38 concentrations 
in plasma and have more pronounced neutropenia(Iusuf et al., 2014).  Although hepatic uptake 
transporters can cause alterations in xenobiotic disposition, efflux transporters are generally 
considered to have the most significant impact(Köck & Brouwer, 2012).  SN-38 and its 
metabolite SN-38G are substrates for MRP2, MRP3, and BCRP, and their disposition is 
significantly affected by the functional status of these transporters(Kato et al., 2002).  While it 
has been previously noted that SN-38 is a substrate for Bcrp and SN-38G is a substrate for 
MRP2(Chu et al., 1997; Kawabata et al., 2001), our data confirm that both compounds are 
substrates for both transporters.  The data herein indicate that biliary efflux of SN-38 and SN-
38G is unchanged either by genetic disruption of Bcrp or the NASH-related disruption of MRP2 
function alone, but the combination of disease and genetic disruption significantly impedes 
biliary efflux.   
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The disposition of SN-38 and its metabolite will also be influenced by the activity of UDP-
glucuronosyltransferases.  UGT1A1 is one of the major isoforms responsible for the 
glucuronidation of SN-38(Etienne-Grimaldi et al., 2015), and variants of UGT1A1 have been 
shown to increase the risk of neutropenia in human patients taking irinotecan(Liu, Cheng, 
Kuang, Liu, & Xu, 2014).  The impact of NASH on UGT expression has been explored in 
previous research; in human patients, there is no change in either the mRNA or protein 
expression of UGT1A1 in when compared to normal(R. N. Hardwick et al., 2013; Lake et al., 
2011).  Similarly, the MCD diet model of NASH had no impact on the mRNA or protein 
expression of UGT1A1 in rats, making it unlikely that alterations to the disposition of SN-38 
glucuronide would be due to the effects of the disease on this enzyme(R. N. Hardwick et al., 
2012).     
Uptake transporters may also have an effect on the disposition of SN-38.  SN-38 is 
known to be transported by human OATP1B1, OATP1B3, and OATP2B1(Fujita, Saito, 
Nakanishi, & Tamai, 2015; Kalliokoski & Niemi, 2009), and rodent transporters OATP1B2, 
OATP2B1, and OATP1A4(Wang et al., 2016), though other transporters of organic anions may 
also be involved.   The MCD diet has been shown to alter the mRNA and protein expression of 
various hepatic uptake transporters, including rat OATP1A1, OATP1A3, OATP1B2, and 
OATP2B1.  Decreases have been observed in the mRNA expression of Oatp1a1, 1a4, 1b2, and 
2b1, while protein expression of Oatp1A1, 1B2, and 2B1 decreases and 1A4 does not 
change(Fisher, Lickteig, Augustine, Oude Elferink, et al., 2009).  While mRNA and protein 
expression of transporters significantly impact drug disposition, the glycosylation status of these 
transporters will also play a role.  The N-linked glycosylation of transporters has multiple 
functions, including protein maturation, stability, and function, and membrane bound proteins in 
particular rely on proper glycosylation for protein folding and trafficking to the appropriate 
membrane(Tannous, Brambilla, Hebert, & Molinari, 2015; Urquhart, Pang, & Hooper, 2005).  In 
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human NASH, it has been observed that genes involved in N-glycan synthesis are down-
regulated, indicating a perturbation of N-linked glycosylation.  This perturbation is reflected in 
the increase in unglycosylated OATP1B1, OATP1B3, OATP2B1, and NTCP protein found in 
human NASH patients(Clarke et al., 2016).  Disruption of normal glycosylation may be one 
mechanism by which NASH alters the function of transporter proteins. 
Inter-individual variability can be accounted for in some cases by genetic 
polymorphisms; the function of hepatic transport proteins, however, can be affected not only by 
genetic variation, but also by disease state.  NASH has been known to cause alterations in 
multiple efflux transporters, including MRP2 and MRP3.  There is a trend towards increased 
efflux transporter expression in NASH in both the human disease and rodent MCD models 
(Canet et al., 2014; R. N. Hardwick et al., 2011).  The interactions of these disease-induced 
alterations with genetic polymorphisms and their functional consequences, however, have not 
been fully determined.  Previous studies have shown gene-by-environment interactions between 
NASH and genetic loss of OATP transporters that affects the disposition of statins(Clarke et al., 
2014).  The plasma and muscle concentrations of pravastatin were synergistically increased in 
Oatp1b2-/- mice with NASH, indicating an increased risk for statin toxicity.  Myopathy is the 
major adverse effect of statin therapy, and it is known to be dose dependent and related to 
plasma concentrations; this synergistic increase between the genotype and disease indicates a 
potential at-risk patient group of those with OATP1B1 polymorphisms and NASH.  We found 
that NASH causes an alteration to the normal hepatobiliary efflux of SN-38 and SN-38G by 
perturbing the MRP2/MRP3 efflux pathway through mislocalization of MRP2 and increased 
expression of MRP3.  Compensation, however, occurs in the form of upregulated BCRP, 
restoring sufficient biliary efflux and leading to no significant alteration in SN-38 or SN-38G 
elimination in the MCD rodent model.  There is a significant gene-by-environment effect 
observed with the addition of a genetic Bcrp knockout to the MCD diet, whereby removal of the 
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compensatory BCRP upregulation results in a sharp decrease in biliary elimination of both 
parent compound and metabolite.  There was no significant increase in plasma AUC over the 
observed time points, though alteration to the plasma retention may only be observable at 
points after the final 40 minute time point.  Similarly, there was no statistically significant 
difference in SN-38 or SN-38G retention in kidney or liver tissues when compared with controls.  
We can therefore conclude that Bcrp plays a role in the disposition of SN-38 and SN-38G along 
with MRP2 and MRP3, and that its function as a compensatory transporter is of increased 
importance in NASH.  As BCRP can compensate for the loss of other transporter function during 
NASH, disrupting its function can restrict the biliary excretion of SN-38 and SN-38G.  Systemic 
retention of SN-38 may increase the risk of toxicity.  It has been previously seen that decreased 
SN-38/SN-38G ratios in plasma are a predictor of the severity of neutropenia in irinotecan 
therapy, though not all irinotecan toxicity could be accounted for by UGT activity(Hirose et al., 
2012; Iyer et al., 2002).  Diminished efflux of SN-38G may also decrease the therapeutic 
efficacy of irinotecan by preventing the intestinal conversion of SN-38G to SN-38 and 
enterohepatic recycling. 
These findings provide a mechanistic basis for variable response to irinotecan therapy 
and identify potential risk in vulnerable populations.  NASH has only recently been identified as 
a factor in drug disposition and ADRs, and due to the invasive liver biopsy required for definitive 
diagnosis, susceptible patients may not be readily identified.  Additionally, genetic variants of 
BCRP are relatively common, and the C421A variant can be found in 39% of Japanese and 
30% of Caucasian populations, producing a transporter with a nonfunctional ATP-binding 
domain(Imai et al., 2002; Kobayashi et al., 2005).  A less abundant variant, G34A, exists in 18% 
of Japanese populations, 6% of African-American populations, and 3% of Caucasian 
populations(Imai et al., 2002; Noguchi, Katayama, Mitsuhashi, & Sugimoto, 2009).  Genetic 
variation in BCRP has also been shown to cause alterations to the pharmacokinetics and 
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pharmacodynamics of drugs on its own(Mizuno, Fukudo, Terada, Kamba, & Nakamura, 2012; 
Zhang et al., 2006), and the combination of genetic polymorphisms and disease could 
potentially compound these changes as demonstrated herein with SN-38.  With the increasing 
prevalence of NASH, the importance of phenoconversion in patients who also have genetic 
polymorphisms is significant. These data provide a possible mechanistic basis for previously 
unidentified causes of variability and toxicity to BCRP substrates in NASH patients.     
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CHAPTER THREE: INTERACTION OF OATP1B2 GENE DOSE AND NONALCOHOLIC 
STEATOHEPATITIS ON PLASMA CLEARANCE OF PRAVASTATIN 
 
Introduction 
In the United States, nearly 1 in 20 hospitalized patients have adverse drug reactions 
(ADR)(Stausberg, 2014).  Various factors may contribute to altered drug responses, including 
genetic polymorphisms of drug-metabolizing enzymes and hepatic transporter proteins that are 
involved in absorption, distribution, metabolism, and excretion (ADME) processes, as well as liver 
diseases.   
Variants of SLCO1B1, the gene encoding the transporter protein OATP1B1, has been shown 
to result in increased plasma concentrations and risk of statin-induced myopathy (SEARCH 
Collaborative Group, 2008; Shitara & Sugiyama, 2006).  Statin drugs, including pravastatin, are 
the first-line therapy for hyperlipidemia and for reducing the risk of heart disease and 
stroke(Mortensen & Falk, 2018).  Although these drugs are incredibly effective, it is estimated that 
up to 40% of eligible patients are not prescribed statins, with one of the major barriers being 
intolerance due to myopathy (Joy & Hegele, 2009).   According to the Prediction of Muscular Risk 
in Observational conditions (PRIMO) study, the incidence of myopathy in high-dose statin patients 
was 10.5%, while 5-18% of patients experienced some muscular symptoms (Bruckert, Hayem, 
Dejager, Yau, & Bégaud, 2005).  As statin toxicity is dose-dependent based on plasma 
concentrations, understanding the mechanisms behind variable drug response can identify 
populations who are at risk for myopathy while on statin therapy (Newman & Tobert, 2018). 
Although genetic polymorphisms are one of the most commonly investigated mechanisms of 
inter-individual variability in statin response, other factors may also modify the pharmaco- and 
toxicodynamic responses of patients.  Liver diseases have been previously found to affect phase 
I and II enzymes and transporters involved in absorption, distribution, metabolism, and excretion 
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(ADME) leading to altered drug disposition (Farrell, Cooksley, & Powell, 1979; Pacifici et al., 1990; 
Thakkar, Slizgi, & Brouwer, 2017).  Nonalcoholic steatohepatitis (NASH), the hepatic 
manifestation of metabolic syndrome, is known to change the activity of xenobiotic transporters 
and significantly influence the disposition of various drugs, including morphine, ezetimibe, and 
pemetrexed (A. L. Dzierlenga et al., 2015; Anika L Dzierlenga et al., 2016; R. N. Hardwick et al., 
2012).  In rodents, the MCD–diet model of NASH recapitulates the observed alterations of hepatic 
transporters, including the downregulation of multiple Oatp transporters resulting elevated 
prolonged plasma concentrations of xenobiotics (Canet et al., 2014; Fisher, Lickteig, Augustine, 
Oude Elferink, et al., 2009).  In Oatp1b2-null mice, MCD diet (NASH) synergistically increases the 
concentrations of pravastatin in plasma and muscle compared to WT mice (Clarke et al., 2014).  
A significant patient population may be at risk for statin-induced myopathy because of the co-
morbidity of compromised function of OATP1B1 (e.g. due to rs4149056 polymorphism of 
OATP1B1, 10-20% in European and Middle-Eastern populations and 10-15% in East Asian 
populations, MAF: 0.24 (Liutkeviciene et al., 2018)) and of NASH (5-17% of the general 
population) (Stewart, 2013). Based on these observations we hypothesized that the combination 
of this liver disease with a partial genetic loss of Oatp1b2 (the rodent analog of human OATP1B1) 
would also result in increased systemic exposure of pravastatin. To test this hypothesis, we 
examined the pharmacokinetic changes of pravastatin after MCD diet in Oatp1b2-null, Oatp1b2-
heterozygote and WT mice.   
Materials and Methods 
Chemicals and Reagents 
Urethane, formic acid, acetontirile, bovine serum albumin, UPLC-grade water, 
iodoacetamide, dithiothreitol, methanol, chloroform, ammonium bicarbonate, sucrose, and Tris 
base were purchased from Sigma Aldrich (St. Louis, MO).  Pravastatin (sodium salt) was 
purchased from Cayman Chemical Company (Ann Arbor, MI).  Protease Inhibitor Cocktail tablets 
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and sequencing-grade trypsin were purchased from Roche (Indianapolis, IN) and Promega 
(Madison, WI) respectively.  3-α-isopravastatin and pravastatin-d3 were purchased from Toronto 
Research Chemicals (Toronto, ON, Canada). 
Animal Breeding and Housing 
Breeders of wild-type C57BL/6 (WT) mice were purchased from Charles River 
Laboratories, Inc.  (Wilmington, MA). Oatp1b2-null mice were engineered in the laboratory of Dr. 
Curtis D. Klaassen and backcrossed (>99% congenic) on C57BL/6 background (Csanaky et al., 
2011; Lu et al., 2008) Male WT, Oatp1b2-/+ (Het), and Oatp1b2-/- (KO) were bred and housed in 
a standard temperature-, light-, and humidity-controlled facility at the University of Kansas Medical 
Center. At four months of age, male WT, Het, and KO mice (6-9 mice per group) were fed either 
a methionine and choline sufficient control diet (# 518810), or a methionine and choline-deficient 
diet (MCD,  518810) for six weeks to induce NASH (Dyets Inc, Bethlehem, PA). 
In Vivo Pharmacokinetic Studies of Pravastatin 
After the six weeks of MCD or control diet feeding, the mice were anesthetized with 
urethane (1.2g/kg), and subsequently, the right carotid artery was cannulated with PE-10 tubing, 
and the common bile duct was cannulated through a high abdominal incision with the shaft of a 
30-gauge needle attached to PE-10 tubing. Throughout the experiment body temperatures of 
mice were maintained at 37°C by rectal probe-controlled heating pads. Depth of anesthesia was 
monitored by pinching the footpad before and throughout surgery, and if necessary, additional 
anesthetic drugs were administered during sample collection. After collection of 5-min pre-bile, 
pravastatin (10 mg/kg/10 ml) was injected via the carotid cannula (0 min). Thirty to 40 µl of blood 
was collected into heparinized tubes at 2, 7.5, 22.5, 37.5, 52.5 and 90 min after pravastatin 
administration. Bile samples were then collected on ice in 15 min periods into pre-weighed 0.6 ml 
microcentrifuge tubes. The volumes of bile samples were determined gravimetrically, taking 1.0 
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as specific gravity.  At 90 min after pravastatin administration the mice were exsanguinated via 
cardiac puncture and liver, kidneys, and gastrocnemius muscle were collected. All blood samples 
were immediately centrifuged at 5,000 x g for 10 min. All samples were snap-frozen in liquid 
nitrogen and stored at -80°C until analysis. The experimental protocol was approved by the 
University of Kansas Medical Center Institutional Animal Care and Use Committee (IACUC), and 
humane care of the animals followed the criteria outlined in the Guide for the Care and Use of 
Laboratory Animals. 
Pravastatin Quantification 
Pravastatin extraction and quantification were according to previously established  
methods (Anika L Dzierlenga et al., 2014; Sparidans, Iusuf, Schinkel, Schellens, & Beijnen, 2010). 
Plasma (20 µl) and bile (20 µl) samples were extracted using the Bond Elut 96 Plexa solid-phase 
extraction plates (Agilent, Santa Clara, CA), according to the manufacturer’s protocol. The solvent 
was then evaporated and the pellets were reconstituted in 120 µl of mobile phase for injections. 
The solid tissues (~300 mg) were homogenized in three volumes of 4% bovine serum albumin.  
Then the proteins in the homogenate were precipitated with UPLC-grade acetonitrile (1:3). The 
samples were vortexed and kept on ice for 10 minutes, and then centrifuged at 13,000 rpm for 10 
minutes. The supernatants were collected in a new microcentrifuge tube and evaporated to 
dryness. The pellets were reconstituted in 120 µl of mobile phase and centrifuged at 10,000 rpm 
for 5 minutes, and the supernatants were used for injections into the LC-MS/MS, as previously 
described (Khan et al., 2005). 
A Waters (Milford, MA) Micromass Quattro Premier XE tandem mass spectrometer coupled to an 
Acquity UPLC was used in the Arizona Laboratory for Emerging Contaminants at the University 
of Arizona.  The chromatographic separations were performed on a Waters Acquity UPLC BEH 
C18 column (1.7 μm, 2.1 × 50 mm) (Milford, MA).   The mobile phase consisted of 0.1% formic 
acid in UPLC-grade water (A) and acetonitrile (B) at a flow rate of 0.3 ml/min. The UPLC gradient 
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ran from 20% to 36% B over four minutes, then equilibrated back to 20% B for one minute before 
the next injection. Pravastatin was detected at m/z 423.3 >303.3, 3-α-isopravastatin at m/z 423.3 
>303.3, and pravastatin-d3 at m/z 426.3 >303.3.   
Membrane Protein Preparation 
Crude membrane fractions were prepared from liver samples based off of a protocol 
adapted from Hirohashi et al (Ogawa et al., 2000).  Approximately 100mg of tissue was 
homogenized in 1 ml of ice-cold ST buffer (sucrose tris buffer, 10mM Tris, 250mM sucrose, pH 
7.5) with one Protease Inhibitor Cocktail table (Roche, Indianapolis, IN) per 50 ml.  The 
homogenates were centrifuged at 10,000xg for 20 minutes to remove nuclei.  The supernatant 
was decanted into 1ml ultramicrocentrifuge tubes and centrifuged at 100,000xg for 30 minutes.  
The resulting pellet was resuspended in ST buffer and stored at -80oC. Protein concentrations 
were determined by Pierce BCA assay kit (Thermo Fisher, Waltham, MA). 
LC-MS/MS Quantification of Transporter Proteins by Surrogate Peptides 
300 μg of crude membrane fraction was diluted into 12 mM dithiothreitol and 15 mM 
ammonium bicarbonate and proteins were denatured by heating at 95oC for 5 minutes. Proteins 
were then alkylated by incubation with 20 mM iodoacetamide in the dark at room temperature 
followed by precipitation with 0.5 ml ice cold methanol, 0.2 ml chloroform, and 0.2 ml water, 
sequentially. Proteins were then pelleted at 16,000 x g at 4℃ for 5 minutes, washed with 0.5 ml 
methanol, and resuspended in 100 µl of 3.7% sodium deoxycholate and 50 mM ammonium 
bicarbonate. Protein samples were then digested with sequencing-grade trypsin (Promega, 
Madison WI) at an enzyme:substrate ratio of 1:100 in a water bath at 37oC overnight.  The next 
day, the reaction was quenched using 0.4% formic acid in water.  Samples were centrifuged at 
16,000 x g for 30 minutes and the supernatant was collected, then desalted on a Waters Oasis 
strong cation exchange solid phase extraction cartridge (Milford, MA) per the manufacturer’s 
73 
 
instructions.  The eluted peptides were dried using a centrivap, reconstituted in mobile phase, 
and 10 µl was separated on a Waters Acquity UPLC BEH C18 column (1.7μm, 2.1 x 50 mm) 
using an Agilent 1290 Infinity II UPLC (Agilent Technologies, Santa Clara CA). UPLC separation 
was achieved by binary gradient flow of water with 0.1% formic acid (mobile phase A) and 90:10 
acetonitrile:water with 0.1% formic acid (mobile phase B) at 0.2 ml/min as follows: 5.5%B (0-2 
minutes), 5.5-33%B (2-22 minutes), 33%B (22-24 minutes), 100%B (24-26 minutes), 5.5%B (26-
28 minutes). The UPLC was connected to a Sciex Qtrap 6500+ triple quadrupole mass 
spectrometer (Framingham, MA) and operated in positive electrospray ionization mode with a 
source voltage of 5.5 kV, curtain gas of 20 psi, nebulizer gas of 50 psi, and turbo gas of 25 psi. 
Surrogate peptide parent (doubly charged, [M+2H]2+) and fragment (singly charged, [M+H]+) 
ions were detected by multiple reaction monitoring (MRM) using a declustering potential of 50 V, 
entrance potential of 10 V, collision energy of 25 V, and collision cell exit potential of 15 V for all 
analytes.  Surrogate peptide sequences and mass transitions were selected using Skyline 
software (MacLean et al., 2010) and unique tryptic peptides were filtered against homologous 
sequences within the host genome by NCBI Protein BLAST; selected MRM transitions can be 
found in Table 1.  Raw data were analyzed using Analyst 1.6.2 (SCIEX, Ontario, Canada). 
Statistical analyses were performed using GraphPad Prism 7. 
Statistics 
All results are represented as the mean ± standard deviation (SD). The differences amongst 
groups (control and NASH animals of each genotype group) were determined by two-way ANOVA 
with Bonferroni post-test, with significance set at P<0.05.   
Results 
Effect of MCD Diet on Plasma Elimination of Pravastatin in Oatp1b2-WT, -HET, and -KO Mice 
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The plasma elimination of pravastatin in the six study groups is depicted in Fig. 3.1. The 
plasma elimination of pravastatin was not significantly influenced by the genotype of the Oatp1b2 
transporter in control-fed mice. However, the plasma concentrations of pravastatin were 
significantly higher in MCD-fed KO mice compared to all other control and MCD fed groups. MCD 
diet increased plasma AUC by 4.4-fold in null-mice. In contrast, MCD feeding did not significantly 
alter the plasma elimination of pravastatin in either WT or HET mice after MCD feeding.  
   
 
 
 
Effect of MCD Diet on Biliary Excretion of Pravastatin in Oatp1b2-WT, -HET, and -KO Mice 
Fig. 3.2 demonstrates the biliary excretion of pravastatin in mice with various genotypes of 
Oatp1b2 fed with control or MCD diet. The genotype of Oatp1b2 did not significantly alter the 
biliary excretion of pravastatin. Similarly, MCD diet did not alter the course of the biliary excretion 
significantly in WT and HET mice; however the peak (-76%) and consequently cumulative 
Figure 3.1.  Effect of MCD diet on plasma elimination of pravastatin in Oatp1b2-WT, -HET, and -KO mice..  Plasma 
concentrations of pravastatin were quantified over 90 minutes after 10 mg/kg dose of pravastatin.  Left panel, plasma 
pravastatin concentration over time for WT-C, WT-MCD, OH-C, OH-MCD, KO-C, and KO-MCD groups. Right panel, 
AUC graph of all groups.  Plasma AUC represents mean ± SD, n=6.  *** P≤.001. 
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excretion (-54%) of pravastatin was significantly decreased in KO mice after MCD feeding. It is 
important to note that the MCD diet decreased the biliary excretion of pravastatin only in the first 
15 min after administration, but not in later periods.   
 
 
 
Effect of MCD Diet on Tissue Concentrations of Pravastatin in Oatp1b2-WT, -HET, and -KO Mice 
Tissue concentrations of pravastatin in liver, kidney, and muscle are shown in Fig 3. 
Neither the genotype nor the MCD-diet significantly influenced the hepatic concentration of 
Figure 3.2.  Effect of MCD diet on biliary excretion of pravastatin in Oatp1b2-WT, -HET, and -KO mice. Left panel, bile 
concentrations of pravastatin were quantified in 15-min periods over 90 minutes after 10 mg/kg dose of pravastatin.  
Right panel, cumulative biliary AUC of pravastatin.Cumulative biliary AUC represents mean ± SD, n=6.  * P≤.05. 
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pravastatin. The various genotype of Oatp1b2 did not significantly change the renal and 
concentration of pravastatin; however the MCD diet dramatically increased the pravastatin 
concentration in kidney (4-fold)  and muscle (21-fold)  in KO, but not in HET and WT mice. 
 
 
Effect of MCD Diet on Protein Abundance of Basolateral Oatp Uptake Transporters in Livers of 
Oatp1b2-WT, -HET, and -KO Mice 
 
 
Figure 3.3. Effect of MCD diet on tissue concentrations of pravastatin in Oatp1b2-WT, -HET, and -KO 
mice.  Pravastatin concentrations per gram of tissue in liver, kidney, and muscle tissue.  Data represents 
mean ± SD, n=6.  ** P≤.01. 
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The effect of MCD diet on Oatp1a1, 1a4, 1b2, and 2b1 transporters are shown in Fig 3.4. 
The amount of Oatp1a1 and 1a4 proteins were not changed by the Oatp1b2 genotype. However, 
the MCD diet almost abolished the male predominant Oap1a1 transporter protein [REF] and 
significantly increased the female predominant Oatp1a4 in all genotypes (WT:+200%; HET: 
+116%; KO: +80%).  The abundance of Oatp1b2 protein was proportional to the Oatp1b2 
genotype. The Oatp1b2 protein was 61% lower in HET than in WT, and practically no Oatp1b2 
Figure 3.4.  Effect of MCD diet on protein abundance of Oatp uptake transporters in livers of Oatp1b2-WT, -HET, and 
-KO mice. A) Relative protein expression of Oatp uptake transporters in wild-type, Oatp1b2-HET (+/-), and Oatp1b2-
null (-/-) mice was determined by proteomic analysis using LC-MS/MS and normalized to Na+/K+-ATPase.  B) 
Representative chromatograms of Oatp1b2 in WT-C and KO-C groups. Top two chromatograms depict native protein 
concentration, and bottom chromatogram depicts housekeeping protein Na+/K+-ATPase. Data represents mean ± SD, 
n=6.  * P≤.05, ** P≤.01, *** P≤.001. 
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protein expression was detected in KO mice. The MCD diet decreased the Oatp1b2 protein by 
67% and 48% in WT and HET mice compared to their corresponding control fed mice, 
respectively. The abundance of Oatp2b1 protein was similar in all genotypes.  However, MCD 
diet decreases the amount of Oatp2b1 in all WT (-66%), HET (-51%) and KO (-55%) mice.   
Effect of MCD Diet on Protein Abundance of Pravastatin Efflux Transporters in Livers of Oatp1b2-
WT, -HET, and -KO Mice 
The effect of MCD diet on hepatic efflux transporters are presented in Fig 3.5.  The 
genotype of Oatp1b2 did not alter the protein abundance of either the canalicular Mrp2 or the 
basolateral Mrp3.  MCD diet had an effect only on the amount of Mrp3 protein, but not on Mrp2 
in all of the Oatp1b2 genotypes. Mrp3 was significantly increased in MCD fed WT (+166%), HET 
(+189%) and KO (+191%), compared to the respective control fed mice.  
 
 
 
 
Effect of MCD diet on Clearance of Pravastatin in Oatp1b2-WT, -HET, and -KO Mice.  
Figure 3.5.   Effect of MCD diet on protein abundance of Mrp2 and Mrp3 efflux transporters in livers of 
Oatp1b2-WT, -HET, and -KO mice. Relative protein expression of Mrp2 and Mrp3 efflux transporters in wild-type, 
Oatp1b2-HET (+/-), and Oatp1b2-null (-/-) mice was determined by proteomic analysis using LC-MS/MS and 
normalized to Na+/K+-ATPase.  Data represents mean ± SD, n=6.  * P≤.05, ** P≤.01. 
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The clearance of pravastatin from plasma was calculated to determine alterations that 
occurred due to diet and Oatp1b2 gene dose (fig 3.6). Clearance was determined as 
CL=Dose/AUC.  MCD diet significantly reduced the clearance of pravastatin across all genotypes.  
However, when the clearance is normalized per body weight, the MCD diet decreased the plasma 
clearance of pravastatin only in KO mice (-88%).    
 
 
 
Figure 3.6.  Pravastatin Clearance. Pravastatin A) clearance and B) weight-adjusted clearance in wild-type, Oatp1b2-HET 
(+/-), and Oatp1b2-null (-/-)  mice.  Data represents mean ± SD, n=6.  * P≤.05, ** P≤.01, *** P≤.001. 
Table 3.1. Peptide Fragments and MRM Transitions for LC-MS/MS Analysis. 
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Discussion  
 The cholesterol-lowering, HMG-CoA reductase inhibitor statins are valuable drugs in 
primary and secondary prevention of cardiovascular diseases. While statin drugs are generally 
considered to be well-tolerated, muscle and consequential kidney toxicities are the primary 
reasons for the exceptionally high rate of discontinuation and low adherence (up to 75%) within 
the first two years of treatment (Stroes et al., 2015).  Discontinuation of statins have significant 
impacts on patient health and mortality, as it has been found that removal of statin therapy 
negatively influences the long-term mortality after a stroke (Colivicchi, Bassi, Santini, & 
Caltagirone, 2007)  and after acute myocardial infarction (Rasmussen, Chong, & Alter, 2007).  
Because there are a large number of patients being prescribed this class of drug, it is crucial to 
identify the groups of individuals who may be at higher risk of muscle and kidney toxicities from 
statin therapy.   
Significant groups of potential risks for statin-induced myopathy are pharmacogenetic variants of 
drug transporters, especially SLCO1B1.  OATP1B1 is a hepatic uptake transporter that is known 
to play an essential role in the disposition and elimination of statin drugs (Hsiang et al., 1999). 
Over 45 variants of OATP1B1 have been identified, some of which have functional consequences 
(Lee & Ho, 2017).  The rs4149056 variant has been associated with increases in plasma 
concentrations of pravastatin in Caucasian and Japanese patients (Niemi et al., 2004; Nishizato 
et al., 2003).  A SEARCH study conducted in 2008 found an association between this 
polymorphism and increased risk of myopathy with high-dose simvastatin (SEARCH 
Collaborative Group, 2008).   Currently, only high-dose simvastatin and cerivastatin have strong 
evidence supporting an increased risk of myopathy with the rs4149056 SNP, and some studies 
have shown no association between this variant and muscle toxicities with other statin drugs 
(Brunham et al., 2012; Carr et al., 2013; Stewart, 2013).  This suggests that additional factors 
other than genetic variation of OATP1B1 alone must be contributing to myopathy in statin therapy. 
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 The data presented in this paper elucidate several aspects of the mechanisms behind 
the interaction between Oatp1b2 polymorphism and NASH on pravastatin pharmacokinetics.  
There is a clear synergistic interaction between diet-induced NASH and the genetic knockout of 
Oatp1b2, which results in delayed elimination of pravastatin.  This effect is the result of the 
disruption of compensatory transport by other Oatp transporter proteins; as pravastatin is a 
substrate of several Oatps, the genetic loss of one transporter protein can be compensated for 
by others, as has been seen in previous studies (Clarke et al., 2014).  Liver diseases such as 
nonalcoholic steatohepatitis are known to downregulate hepatic uptake transporters, such as 
OATPs, which is recapitulated in the rodent MCD model (Canet et al., 2014; Lake et al., 2011).  
This disruption of compensatory transport could explain the modest and inconsistent association 
of rs4149056 with muscle toxicity and statin pharmacokinetics and also indicates that the overlap 
between NASH patients and patients with specific OATP1B1 polymorphisms may be at increased 
risk of myopathy.  Though the Oatp uptake transporters play a distinct role in the disposition of 
statin drugs, efflux transporters are a significant mediator of disposition and have an impact on 
pravastatin concentrations. Although MCD diet (NASH) minimally alters the plasma AUC of 
pravastatin in WT and HET mice, there is a synergistic effect between the total loss of functional 
Oatp1b2 and MCD diet in KO mice. The pravastatin AUC increased 4.4-fold in KO mice as the 
consequence of 78% decrease in plasma clearance (Fig 2). In MCD-,fed HET mice the single 
copy of functioning Oatp1b2 (high capacity/high affinity) and the alternative compensatory 
transport processes seem to still effectively sustain the elimination of pravastatin, avoiding the 
toxic accumulation of pravastatin in muscle and kidneys. However, in case of total functional loss 
of Oatp1b2 in mice with NASH, the compensatory mechanisms are not enough to substitute for 
the lost capacity of Oatp1b2, causing a 21-fold and 4-fold increase in pravastatin concentrations 
in the muscle and kidneys, respectively.   
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 Protein and mRNA expression of Oatp transporters, however, may not be the only factor 
impacting their function.  Transporter proteins are often glycosylated for stability, as well as for 
proper folding, trafficking, and localization (Tannous et al., 2015; Urquhart et al., 2005).  A 
downregulation of N-glycan synthesis genes has been noted in human NASH, which may then 
disrupt N-linked glycosylation; this is evidenced by an increase in unglycosylated OATP1B1, 
OATP1B3, OATP2B1, and NTCP in human NASH patients (Clarke et al., 2016).  This represents 
one potential mechanism for how NASH alters the function of transporter proteins outside of 
protein or mRNA expression. 
 It is also important to mention that besides basolateral uptake transporters, changes in 
canalicular transporters may also alter the pharmacokinetics of pravastatin. In Mrp2-null  rats, the 
plasma AUC of pravastatin increased after both oral and intravenous administration due to 
decreased biliary efflux(Kivistö et al., 2005).  The MCD diet that was used in our study to induce 
NASH also decreases Mrp2 function due to mislocalization from the canalicular membrane (Anika 
L Dzierlenga et al., 2016).  MCD diet decreased the cumulative biliary excretion only in Oatp1b2-
null mice (Fig 2). It is important to emphasize that this difference was due to the significant 
decrease in the early peak excretion of pravastatin (0-15 min), but no later effects on later 
excretion. This finding suggests that the hepatic uptake of pravastatin via Oatp1b2 is the key rate-
limiting factor for the peak biliary excretion of pravastatin, contrary to the decreased abundance 
of canalicular efflux transporter Mrp2. In addition to decreases in Mrp2, the MCD diet is known to 
decrease the mRNA expression of Bsep, a membrane-associated ATP-binding cassette 
transporter that is a major mediator of bile formation and flow (Lickteig et al., 2007).  Although 
Bsep has a high degree of homology with Mdr1, the transporter does not share the same broad 
substrate specificity as Mdr1 and mainly exports bile acids.  While it has been shown that 
pravastatin is a substrate for Bsep using membrane microsomes expressing rodent and human 
BSEP (Hirano, Maeda, Hayashi, Kusuhara, & Sugiyama, 2005), the contribution of Bsep to the 
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biliary clearance of pravastatin in vivo is questionable, because in Bsep-null rats the 
pharmacokinetics of pravastatin is not altered (Cheng et al., 2016).  MCD diet also increased the 
abundance of Mrp3 in the basolateral membrane, which potentially contributes to the back 
transport of the pravastatin from the liver to the blood. The increase in Mrp3 protein may become 
an important factor only when the function of Oatp1b2 is entirely lost (Fig 5). This hypothesis is 
also supported by the observation that MCD diet (NASH) did not alter the hepatic pravastatin 
concentration in any of the genotypes.   
 In conclusion, it is important to carefully interpret the present results, because the direct 
translation of these data to humans is difficult due to the differences in the expression and 
substrate specificity of human and rodent Oatps orthologs.  However, these data are valuable in 
the modeling of important mechanisms impacting the pharmacokinetics of pravastatin and sheds 
light on essential factors, affecting the disposition and potential toxicity of statin drugs in NASH 
patients.  These data demonstrate that under certain circumstances confounding factors like 
NASH and genetic polymorphism have a significant impact on drug disposition and toxicity, and 
the difficulties associated with definitively diagnosing NASH presents issues with identifying at-
risk patients.  Based on these findings, NASH patients with heterozygous polymorphisms with 
one functional copy of the gene may not be at higher risk of muscle toxicity but administering 
statins may require special cautions for homozygous populations. 
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CHAPTER FOUR: NONALCOHOLIC STEATOHEPATITIS INCREASES PLASMA 
RETENTION OF SORAFENIB-GLUCURONIDE BY ALTERING THE MECHANISMS OF 
HEPATOCYTE HOPPING 
Introduction  
Nonalcoholic steatohepatitis (NASH) is the hepatic manifestation of metabolic syndrome, and 
disease progression from nonalcoholic fatty liver disease (NAFLD) to NASH presents with 
fibrosis, inflammation, and hepatocellular injury(Marra et al., 2008).  The overall prevalence of 
NASH is approximately 1.5-6.45%(Z. M. Younossi et al., 2016).  The progression to NASH also 
presents with significant alterations to gene expression, including genes that are responsible for 
ADME (absorption, disposition, metabolism, excretion) processes, such as xenobiotic 
transporters and drug metabolizing enzymes(Lake et al., 2011).  These alterations can 
drastically change the disposition and toxicity of xenobiotics, potentially resulting in adverse 
drug reactions.  As nearly 1 in 20 hospital patients experience ADRs in the United 
States(Bourgeois et al., 2010), identifying the factors that contribute to variations in drug 
response is of increasing importance.   
Sorafenib (SFB) is a kinase inhibitor chemotherapeutic used in the treatment of renal cell 
carcinoma, hepatocellular carcinoma, and radioactive iodine-resistant thyroid cancer.  Patient 
response to sorafenib treatment, however, is variable(Rimola et al., 2018; Takeda et al., 2014), 
even though the metabolic pathways through CYP3A4-mediated formation of sorafenib-N-oxide 
and UGT1A9-mediated formation of sorafenib-glucuronide (SFB-G) have been reasonably well 
characterized(Edginton, Zimmerman, Vasilyeva, Baker, & Panetta, 2016; Ye et al., 2014).  This 
presents difficulties in predicting patients who are at risk for adverse events.  Previously, it has 
been observed that Oatp1a/1b cluster knockout mice, which lack several basolateral hepatic 
uptake transporters, experience increased SFB-G plasma concentrations after an oral dose of 
SFB(Vasilyeva et al., 2015).  Conjugated glucuronide compounds like SFB-G and bilirubin-
86 
 
glucuronide have been found to undergo a shuttling process into and out of hepatocytes, 
mediated through basolateral OATP uptake transporters and basolateral excretion via MRP3 
and other unidentified transporters.    This process, described by Vasilyeva et al. as ‘hepatocyte 
hopping’, is a normal physiological process that allows for relatively efficient hepatic elimination 
through multiple opportunities at excretion(Vasilyeva et al., 2015).  In the hepatocyte hopping 
process, 1.) metabolites are either returned to sinusoidal blood through MRP3 , or 2.) secreted 
into bile through MRP2. , Finally, each subsequent hepatocyte that the compound encounters 
through downstream OATP uptake will afford another chance at MRP2 excretion.  Thus, if 
biliary secretion in upstream hepatocytes is saturated, either due to incidental inhibition or 
overload, biliary secretion is distributed more evenly across the entire lobule and glucuronidated 
substrates can still be eliminated(Iusuf et al., 2012).   
Nonalcoholic steatohepatitis has been known to alter the disposition of drugs through alteration 
of hepatic xenobiotic transporter expression and function(Anika L Dzierlenga et al., 2016; Toth 
et al., 2018).  Among the affected transporters are OATP uptake transporters, MRP2, and 
MRP3, all of which play critical roles in the hepatocyte hopping of glucuronidated substrates.  
Given previous data on the effects of NASH on xenobiotic disposition, it was hypothesized that 
hepatocyte hopping of SFB-G would be disrupted by NASH, resulting in increased plasma 
concentrations.  This study aimed to determine the impact of NASH on the three molecular 
mechanisms of SFB-G hepatocyte hopping using the MCD diet model of NASH in combination 
with rodent knockout models to isolate the effect of disease on hepatocellular shuttling. 
Materials and Methods 
Reagents 
Sorafenib was purchased from Sigma Aldrich (St Louis, MO).  Sorafenib-methyl-d3 was 
purchased from Santa Cruz Biotechnology (Dallas, TX).  Sorafenib-glucuronide standard was 
87 
 
generously donated by Dr. Sharyn Baker from Ohio State University (Columbus, OH).  
Cremophor EL, UPLC-grade acetonitrile, and UPLC-grade water were purchased from Sigma 
Aldrich.  ReadyScript® cDNA synthesis kit, KiCqStart™ SYBR® green qPCR  master mix, and 
PCR primers for Oatp1a1, Oatp1a4, Oatp2b1, Oatp1b2, Mrp2, Mrp3, and β-actin (Actb) were 
obtained from Sigma-Aldrich.  RNA Bee isolation reagent was obtained from Amsbio 
(Cambridge, MA).  Synthetic peptides for targeted proteomic analysis were purchased from 
AnaSpec Inc (Fremont, CA).   
Animals 
Male FVB wild-type and Oatp1a/1b-/- mice from Jackson Laboratory (Bar Harbor, ME) at 8 
weeks of age were housed in a standard 12-hour light/dark cycle in the University of Arizona 
animal care facility.  Male C57Bl6J and Mrp2-/- mice at 8 weeks of age from the Aleksunes lab 
(Piscataway, NJ) were housed in the Rutgers University animal care facility.  The mice were 
given either a methionine and choline sufficient (control) diet or a methionine and choline 
deficient (MCD) diet from Dyets, Inc (Bethlehem, PA) for 6 weeks to induce NASH.  After the 6 
weeks of diet, a stock solution of 2.5 mg/mL of sorafenib was made by dissolving sorafenib in a 
1:1 mixture of Cremophor EL and 100% ethanol, then diluting 1:4 in deionized water.  The 
animals were given an oral gavage of 10 mg/kg of sorafenib (5 mL/kg).  Blood collections were 
taken at 20 minutes, 1, 2, 4, and 8 hours via submental bleed after sorafenib administration into 
heparinized tubes.  Plasma was obtained via centrifugation.  After the final time point, the 
animals were euthanized by CO2 box and terminal liver was collected.  Plasma samples were 
stored at -80oC, and tissue samples were flash-frozen in liquid nitrogen before being stored at -
80oC.  The animal study was approved by the University of Arizona Animal Care and Use 
Committee and the Rutgers University Animal Care and Use Committee. 
Sorafenib Quantification 
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The method for quantification of sorafenib-glucuronide was adapted from previously established 
methods(Sparidans et al., 2009; Vasilyeva et al., 2015).  The Arizona Laboratory for Emerging 
Contaminants provided a Waters (Milford, MA) Micromass Quattro Premier XE tandem mass 
spectrometer coupled with an Acquity UPLC.  The mobile phase consisted of UPLC-grade water 
with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid (B).  A Waters Acquity UPLC 
BEH C19 column (1.7μm, 2.1 x 50 mm) was used for separation and set to a flow rate of 0.3 
mL/min.  The UPLC gradient began at 60% A, then decreased to 35% A from 1.0-1.70 minutes 
and held until 2.50 minutes.  After 2.50 minutes, A decreased to 5% and held until 4.50 minutes 
before returning to 60% A and equilibrating for 1 minute.  Sorafenib was detected at 465.1>270, 
Sorafenib-glucuronide was detected at 641.2>465.1, and Sorafenib-methyl-d3 (internal 
standard) was detected at 468>255.  The assay was validated between 10-10,000 ng/mL for 
sorafenib and 10-30,000 ng/mL for sorafenib-glucuronide, with the lowest limit of these ranges 
being the lower limit of quantification (LLOQ).  Raw data were processed using the Waters 
MassLynx software and statistical analyses were done using GraphPad Prism 7 (GraphPad 
Software, San Diego, CA). 
Tissue Preparation 
Liver tissue was prepared for LC-MS/MS quantification of sorafenib-glucuronide.  200 mg of 
tissue was homogenized in 400 µL of cold 4% (w/v) bovine serum albumin in UPLC-grade 
water.  20 µL of homogenate was placed into a 1.5 mL microcentrifuge tube and combined with 
5 µL of internal standard.  40 µL of acetonitrile was added to precipitate proteins and then the 
mixture was vortexed vigorously.  The homogenate was centrifuged at 10,000xg and the 
supernatant was pipetted into a 250 µL glass insert and diluted to a total volume of 120 µL with 
mobile phase. 
Protein Preparation 
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Crude membrane preparations were prepared from liver tissue samples.  Approximately 100 mg 
of tissue was homogenized in 1 mL of cold ST buffer (sucrose Tris buffer; 10 mM Tris base and 
250 mM sucrose) with protease inhibitor (Roche, Indianapolis, IN).  Homogenates were 
centrifuged at 10,000xg for 20 minutes to remove nuclei and the supernatant was decanted into 
a second set of ultracentrifuge tubes. The supernatant was spun at 100,000xg for 60 minutes to 
pellet the membranes. Membrane pellets were rinsed with buffer, then resuspended in 100 µl 
buffer and stored at -80oC.  Protein concentrations were determined via BCA assay (Thermo 
Fisher, Waltham, MA). 
Proteomic Quantification of Transporter Proteins 
Denaturing buffer was prepared, consisting of 3.7% sodium deoxycholate in 100mM of 
ammonium bicarbonate.  Crude membrane preparations were diluted to 300 µg in 100 µL of 
denaturing buffer.  Samples were reduced by adding DTT to a final concentration of 6 mM and 
incubated for 5 minutes at 95oC.  The samples were then alkylated by adding iodoacetamide to 
15 mM and incubating for 30 minutes at room temperature.  Protein digestion was then 
performed using sequencing-grade trypsin at an enzyme:substrate ratio of 1:100.  Proteins were 
digested in a water bath at 37oC overnight.  The next day, the reaction was quenched using 
0.4% formic acid.  Samples were centrifuged at 16,000 xg for 30 minutes and the supernatant 
was collected, then desalted on a Waters Sep Pak C18 solid phase extraction cartridge (Milford, 
MA) as per the manufacturer’s instructions.  The eluted peptides were dried down using a 
centrivap.  Samples were then reconstituted in mobile phase and run on a Sciex Qtrap 6500 
with triple quad LC-MS/MS system (Framingham, MA) using a Waters Acquity UPLC BEH C19 
column (1.7μm, 2.1 x 50 mm).  Mobile phase consisted of 0.1% formic acid in water (A) and 0.1 
% formic acid in 80% acetonitrile (B).  Runs were 30 minutes long at 0.2 mL/min with a 10 µL 
injection volume.  The UPLC gradient ran at 5.5% B from 0-2 minutes, then increased to 33.3% 
B from 2-22 minutes, held at 33% B until 24 minutes, then increased to 100% B from 24-26 
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minutes.  The gradient then returned to 5.5% B from 26-28 minutes and maintained for 2 
minutes before the start of the next run.  Raw data were analyzed using Analyst 1.6.2 (SCIEX, 
Ontario, Canada).   Protein fragments and MRM transitions can be found in table 1.  Statistical 
analyses were performed in GraphPad Prism 7. 
Quantitative Reverse Transcription-PCR 
RNA was isolated from liver tissue using RNA Bee isolation reagent (Amsbio, Cambridge, MA).  
200-300 mg of tissue was added to 4 mL of RNA Bee and homogenized.  Following the 
manufacturer’s protocol, the RNA pellet was reconstituted in 250 µL of DEPC water per 100 mg 
of tissue, then stored at -80oC.  RNA concentration was determined via NanoDrop 200 UV-Vis 
spectrophotometer (Thermo Fisher Scientific, Waltham, MA) and final RNA preparations had a 
260/280 quality ratio between 1.6 and 1.9.  ReadyScript® cDNA synthesis kit (Sigma Aldrich, St 
Louis, MO) was used to prepare cDNA.  Each reaction well contained 2 µL of cDNA template, 
100 nM of forward and reverse primers, 1x KiCqStart™ SYBR® green master mix, and 
nuclease free water up to 20 µL, run in duplicate.  mRNA concentrations were measured using 
an ABI StepOnePlus Real Time PCR system with a standard SYBR® green PCR cycling profile.  
Delta-delta CT method was used to determine fold change. 
Histopathology  
Paraffin-embedded liver sections were stained with H&E and then examined by a board-certified 
veterinary pathologist. Tissues were incidence and severity scored using an established rodent 
NASH system(Kleiner et al., 2005) with endpoints including steatosis, necrosis, inflammation, 
hyperplasia, and biliary hyperplasia. Representative digital images were acquired. 
Statistics 
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All results are represented as the mean ± standard deviation (SD).  Two-way ANOVA analyses 
with Bonferroni post-test were used to compare between groups.  Student t-test was used to 
compare between two groups.  Each group contained n=6 animals. 
Results 
Effects of Diet-Induced NASH and Oatp1a/1b Cluster Knockout on Sorafenib-Glucuronide 
Disposition 
H&E stained liver sections were examined under a light microscope at 40x magnification to 
determine disease severity.  NASH hallmarks were observed in mice fed an MCD diet for 6 
weeks, including steatosis, inflammation, fibrosis, necrosis, and biliary hyperplasia (fig 4.1).  
This recapitulates the disease as seen in human patients and is consistent with previous 
findings(Canet et al., 2014; Kleiner et al., 2005). The effects of NASH and Oatp1a/1b cluster 
knockout were determined over the course of 8 hours.  Plasma AUC levels of SFB-G increased 
by 108-fold in the O-/--C group when compared to the WT-C.  The WT-NASH group showed a 
165-fold increase in SFB-G plasma concentrations when compared to its control.  When 
compared to O-/--C group, the O-/--NASH group increased by 3.2-fold (fig 4.2).  These data 
indicate that Oatp function is one determinant in the disposition of SFB-G, and the alterations to 
transporter function that occurs in NASH also impact SFB-G plasma concentrations. 
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Fig 4.1.  Liver histopathology of control and diet-induced NASH mice.  H&E-stained liver sections of control 
rats and rats fed 8 weeks of MCD diet; WT, Oatp1a/1b cluster KOs, and Mrp2 KOs.  Original magnification, 
40×. 
 
Fig 4.2.  Effects of Oatp1a/1b cluster knockout and NASH on plasma sorafenib-glucuronide concentration.  Plasma 
concentrations were taken over 8 hours after 10 mg/kg dose of sorafenib.  Plasma AUC represents mean ± SD, n=6.  
* P≤.05, ** P≤.01, *** P≤.001. 
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Effects of Diet-Induced NASH Mrp2 Knockout on Sorafenib-Glucuronide Disposition 
The effects of NASH and Mrp2 knockout were determined over a period of 8 hours.  The 
concentrations of SFB-G in the plasma of the Mrp2-/- -C mice increased by 334.7-fold when 
compared to the WT-C mice.  Concentrations of SFB-G in plasma increased by 67.5-fold in the 
WT-NASH group when compared to the WT-C group.  The Mrp2-/- -NASH group saw a 1.18-fold 
increase in SFB-G plasma concentrations when compared with the Mrp2-/- -C group (fig 4.3).  
These data indicate that Mrp2 function is the major determinant of SFB-G disposition, but not 
the sole mediator. 
 
 
 
Effects of Diet-Induced NASH and Oatp1a/1b Cluster Knockout on Liver Concentrations of 
Sorafenib-Glucuoronide 
Hepatic concentrations of SFB-G were determined in order to assess the effect of diet-induced 
NASH and Oatp1a/1b cluster knockout on drug disposition.  In the WT-NASH group, the 
Fig 4.3.  Effects of Mrp2 knockout and NASH on plasma sorafenib-glucuronide concentration.  Plasma concentrations 
were taken over 8 hours after 10 mg/kg dose of sorafenib.  Plasma AUC represents mean ± SD, n=6.  * P≤.05, ** 
P≤.01, *** P≤.001. 
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concentration of SFB-G decreased to 76% of its control, and in the O-/--NASH group, the 
concentration decreased to 67% of its control.  When comparing the O-/--C group with the WT-C 
group to assess the impact of loss of Oatp1a/1b function alone, the SFB-G concentrations in the 
O-/--C group decreased to 57% of the WT-C group.  When comparing the O-/--NASH group to 
the WT-C, the concentration of SFB-G in the liver decreased to 38% of control (fig 4.4).  These 
data indicate that Oatp function contributes significantly to the uptake of SFB-G into 
hepatocytes, and loss of function results in decreased hepatic concentrations.  The alterations 
to transporter function that occurs during NASH also impede Oatp-mediated uptake and 
retention in hepatocytes, resulting in lowered liver concentration. 
 
 
 
Effects of Diet-Induced NASH and Mrp2 Knockout on Liver Concentrations of Sorafenib-
Glucuronide 
To assess the effect of diet-induced NASH and Mrp2 knockout on drug disposition, the 
concentration of SFB-G in the liver tissue was determined.  In the WT-NASH group, the 
Fig 4.4.  Effects of Oatp1a/1b cluster knockout and Mrp2 knockout and NASH on liver tissue sorafenib-glucuronide 
concentration.  SFB-G concentration in liver tissue in (A) Oatp1a/1b cluster knockout mice and (B) Mrp2 knockout 
mice.  Data represents mean mean ± SD, n=6.  * P≤.05, ** P≤.01, *** P≤.001. 
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concentration of SFB-G decreased to 55% of its control, while the concentration of SFB-G in the 
Mrp2-/- -NASH group decreased to 15% of its control.  When assessing the impact of the genetic 
loss of Mrp2 function alone, the SFB-G concentrations in the Mrp2-/- -C group increased to 239% 
of the WT-C group.  Between the Mrp2-/- -NASH group and the WT-C, the concentration of SFB-
G in the liver decreased to 36% of control (fig 4.4).  These data indicate that Mrp2 function 
contributes significantly to the efflux of SFB-G from hepatocytes, and loss of function will result 
in hepatic accumulation of the glucuronide.  Loss of function of Mrp2 combined with disruption 
of hepatocyte hopping due to diet-induced NASH, however, results in an even greater decrease 
in hepatic accumulation of SFB-G.   
 
 
Fig 4.5.  Altered mRNA expression of Oatp and Mrp transporters due to Oatp1a/1b cluster knockout and Mrp2 knockout and 
diet-induced NASH.  mRNA expression of Oatp transporters and Mrp transporters in (A) Oatp1a/1b cluster knockout mice and 
(B) Mrp2 knockout mice was determined through qRT-PCR and fold change was determined using the ΔΔCT method.  Data 
represents mean mean ± SD, n=6.  * P≤.05, ** P≤.01, *** P≤.001. 
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Effects of Diet-Induced NASH and Oatp1a/1b Cluster Knockout and Mrp2 Knockout on 
Xenobiotic Transporter Gene Expression 
mRNA expression of Oatp uptake transporters and Mrp efflux transporters was assessed to 
determine the impact of NASH, Oatp1a/1b cluster knockout, and Mrp2 knockout on gene 
expression.  The gene expression of Oatp1a1 decreased to 36% of control in the WT-NASH 
group, and there was no mRNA detected in the O-/--C or O-/--NASH groups.  In the Mrp2-/- -
NASH group, the expression of Oatp1a1 decreased to 10% of control.  The gene expression of 
Oatp1a4 increased to 167.6% of control in the WT-NASH group, to 181% of control in the Mrp2-
/- -NASH group, and had no expression in either of the Oatp1a/1b knockout groups.  The gene 
expression of Oatp1b2 decreased to 63% of control in the WT-NASH group, to 44% of control in 
the Mrp2-/- -NASH group, and had no expression in either of the O-/- groups.  The expression of 
Oatp2b1 decreased to 52%, 58%, and 56% of control in the WT-NASH, O-/--C, and O-/--NASH 
groups, respectively.  Oatp2b1 expression also decreased to 40% of control in the Mrp2-/- -
NASH group.  There were no statistically significant alterations to the mRNA expression of Mrp2 
across any of the groups.  Mrp3 expression was only significantly altered in the Mrp2-/- -NASH 
group, where it increased to 479% of control. (fig 4.5).    
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Effects of Diet-Induced NASH and Oatp1a/1b Cluster Knockout and Mrp2 Knockout on 
Xenobiotic Transporter Protein Expression 
Relative protein concentrations of Oatp1a1, Oatp1a4, Oatp1b2, Oatp2b1, Mrp2, and Mrp3 were 
determined via LC-MS/MS and normalized to Na+/K+-ATPase (NaK).  Oatp1a1 protein 
expression decreased to 57.2% of control in the WT-NASH group, to 10.8% of control in the 
Mrp2-/- -NASH group, and was not detected in the Oatp1a/1b cluster knockout animals.  
Oatp1a4 protein expression increased to 326.6% of control in the WT-NASH group, to 806.3% 
of control in the Mrp2-/- -NASH group, and was not detected in Oatp1a/1b cluster knockout 
animals.  Oatp1b2 protein expression decreased to 50.5% of control in the WT-MCD group, to 
Fig 4.6.  Altered protein expression of Oatp and Mrp transporters due to Oatp1a/1b cluster knockout and Mrp2 
knockout and diet-induced NASH.  Relative protein expression in (A) Oatp1a/1b cluster knockout mice and (B) Mrp2 
knockout mice was determined by proteomic analysis using LC-MS/MS and normalized to Na+/K+-ATPase expression 
with Mrp2 heavy labeled internal standard.  Data represents mean ± SD, n=6.  * P≤.05, ** P≤.01, *** P≤.001. 
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32.9% of control in the Mrp2-/- -NASH group, and was not detected in the Oatp1a/1b cluster 
knockout animals.  Oatp2b1 protein expression decreased to 48.1% of control in the WT-MCD 
group, to 42.1% of control in the Mrp2-/- -NASH group, and to 42.0% of control in the O-/--NASH 
group.  Mrp3 protein expression increased to 425.4% of control in the WT-NASH group, to 
244.6% of control in the Mrp2-/- -NASH group, and to 386.3% of control in the O-/--NASH group. 
The protein expression of Mrp2 did not significantly change between any group, and no Mrp2 
protein was detected in the Mrp2 knockout groups. (fig 4.6). 
Protein Fragment Q1 Mass Q3 Mass 
NaK R.AAVPDAVGK.C  414.2 586.3 
Oatp1a1 K.GVQHPLYGEK.N 564.3 706.3 
Oatp1a4 K.YLEQQYGK.S 514.8 495.2 
Oatp1b2 K.ALGGVIMK.S 400.7 486.2 
Oatp2b1 R.VVQEALGK.S 422.3 517.3 
Mrp2 R.INEYINVDNEAPWVTDK.K 1010.4 1174.5 
Mrp3 K.ILSALAEGK.I  451.3 588.3 
   
Discussion 
The disposition of SFB-G is mediated by sinusoidal efflux through Mrp3, biliary efflux via Mrp2, 
and sinusoidal uptake through Oatp transporters.  During the progression of NASH, previous 
research in human patients has identified alterations to enzymes and transporters responsible 
for drug disposition(Lake et al., 2011). These alterations result in nearly identical changes to the 
functional disposition of several drugs in both human and rodent models of NASH. Importantly, 
the three mechanisms of hepatocyte hopping are concordantly regulated in both human NASH 
and MCD diet-induced NASH, and drugs that rely on any one of these three mechanisms show 
strikingly similar changes in disposition.  In the case of APAP, after the administration of a 
nontoxic dose, the biliary concentrations of the 3 major metabolites (APAP-sulfate, APAP-
glucuronide, APAP-glutathione) were significantly decreased in rats with diet-induced NASH.  
Table 4.1. Peptide Fragments and MRM Transitions for LC-MS/MS Analysis. 
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Additionally, the Mrp3 substrate APAP-glucuronide was elevated in NASH rat plasma when 
compared to the other metabolites, and was also 80% higher in urine. (Lickteig et al., 2007)  
The increased levels of APAP-glucuronide in serum and urine that were found in the MCD 
rodent model also presented only in patients with NASH.  This shift indicates that the increased 
expression of Mrp3 and mislocalization of Mrp2 in the MCD model of NASH is identical to that 
observed in human NASH patients (Canet et al., 2015).  There was a similar agreement 
between the changes to morphine pharmacokinetics in the MCD rat model and human patients, 
showing an increase in systemic morphine-glucuronide exposure, and an increase in serum 
exposure of M3G due to decreased biliary efflux and increased sinusoidal efflux of the 
metabolite(A. L. Dzierlenga et al., 2015; Ferslew et al., 2015; Pierre et al., 2017).  .  While the 
extrapolation of animal data to predict toxicity in humans remains challenging, the MCD diet-
induced model of NASH offers utility in that it closely resembles human NASH histology and 
recapitulates the molecular mechanisms of hepatic transporter alterations found in human 
patients(Canet et al., 2014; Li, Toth, & Cherrington, 2017).               
 In addition to the ABC efflux transporters, Oatp uptake transporters play a crucial role in the 
hepatocyte hopping process and are altered during the progression of NASH..  The MCD diet 
has been shown to recapitulate the alterations observed in human disease and alter the protein 
and mRNA expression of several Oatp proteins, including Oatp1a1, Oatp1a4, Oatp1b2, and 
Oatp2b1.  In the rodent model, the mRNA expression of Oatp1a1, Oatp1b2, and Oatp2b1 have 
been shown to decrease, whereas the expression of Oatp1a4 increases.  Similarly, the protein 
expression of Oatp1a1, Oatp1b2, and Oatp2b1 decrease, while expression of Oatp1a4 
increases(Clarke et al., 2014).  Disease-related transporter impairment is known to significantly 
decrease the hepatic uptake of 99mTc-mebrofenin, a known substrate of OATP1B1 and 
OATP1B3, in human patients(I. Ali et al., 2017).  It has also been previously established that 
alterations to Oatp uptake transport can have a significant impact on the disposition of SFB and 
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SFB-G(Zimmerman et al., 2013), as well as other xenobiotics like SN-38(Iusuf et al., 2014).  In 
the MCD rodent model, the interaction of NASH and Oatp1b2 knockout was shown to 
significantly increase plasma and muscle concentrations of pravastatin, potentially leading to an 
increase in toxicity(Clarke et al., 2014).  In addition to hepatic uptake transporters, efflux 
transporters are also known to have a significant impact on drug disposition.  In the MCD rodent 
model of NASH, the disease causes an increase in the protein expression of Mrp3 and no 
change in the overall protein expression of Mrp2(Canet et al., 2014); however, the function of 
Mrp2 is significantly impaired due to mislocalization of the transporter from the bile canalicular 
membrane(A. L. Dzierlenga et al., 2016). This has been shown to impact the distribution of 
various xenobiotics such as pemetrexed, methotrexate, and ezetimibe(Anika L Dzierlenga et al., 
2016; R. Hardwick et al., 2014; R. N. Hardwick et al., 2012).  As SFB-G is known to be a 
substrate for Oatp uptake transportersand Mrp2, the functional status of these transporters will 
significantly impact the disposition of this compound.  While Mrp3 is also known to be a 
contributor to the sinusoidal efflux of SFB-G, full genetic knockout of this protein has only a 
modest impact on pharmacokinetics(Vasilyeva et al., 2015), implicating the participation of an 
unknown transporter in this process. 
There is evidence that the glycosylation status of transporter proteins is altered during NASH, 
and the presence or absence of these modifications also impact the function of the protein.    N-
linked glycosylation of transporter proteins serves several different purposes, including stability, 
function, and localization, and membrane-bound proteins require proper glycosylation for 
trafficking(Tannous et al., 2015; Urquhart et al., 2005).  Several genes associated with N-linked 
glycosylation are downregulated in human NASH, indicating a possible perturbation; this is 
supported by an increase in unglycosylated OATP1B1, OATP1B3, OATP2B1, and NTCP in 
human NASH patients(Clarke et al., 2016).  Impairment of N-linked glycosylation may be one 
mechanism by which NASH disrupts xenobiotic transporter function. 
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The disposition of SFB-G can also be affected by the activity of UDP-glucuronosyltransferases, 
though it is unlikely that UGT1A9 metabolism is a significant contributor to the variability in SFB-
G disposition found in NASH.  Uridine 5’-diphosphoglucuronosyltransferase (UGT) 1A9 is the 
major isoform responsible for the glucuronidation of SFB(Bins et al., 2017), and some 
polymorphisms of UGT1A9 have been associated with increased risk of toxicity in patients 
taking SFB(Boudou-Rouquette et al., 2012).  In human NASH patients, UGT1A9 protein 
expression is downregulated(R. N. Hardwick et al., 2013), and a similar decrease was observed 
in the mRNA expression of this enzyme in steatotic mice(Merrell & Cherrington, 2011).  This 
makes it unlikely that the alterations to the disposition of SFB-G would be due to the effects of 
NASH on the expression of the enzyme. 
   Systemic inflammation and other disease processes could provide the mechanistic basis for 
the larger category of interindividual variability that cannot be explained by genetics. Disease 
state, however, can also be a factor that impacts the expression and function of hepatic 
xenobiotic transporters.  Xenobiotic transporters from both the Oatp and Abcc families are 
known to be significantly altered during the progression of NASH, leading to significant changes 
in drug disposition.  Previous studies have investigated the synergistic effects of gene-by-
environment interactions of NASH and hepatic transporter polymorphisms, and found that the 
interaction between NASH and deleterious polymorphisms can result in significant increases in 
plasma exposure and potential toxicity of xenobiotics(Clarke et al., 2014; Toth et al., 2018).  
This is the first study to attempt to isolate the mechanisms involved in hepatocyte hopping and 
quantitate their impact on pharmacokinetics in NASH.  The effects can be readily seen in the 
significant increase in SFB-G plasma concentrations when comparing the WT-NASH group to 
its control, as well as in the 3.2-fold increase in plasma concentrations when comparing the O-/--
NASH group to the O-/--C group.  Disruption of Oatp uptake in the knockout group prevents the 
reuptake of SFB-G into downstream hepatocytes, prolonging plasma exposure.  The additional 
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alterations to Mrp2 and Mrp3 function due to the effects of diet-induced NASH further 
exacerbate the disruption to hepatocyte hopping, as the loss of Mrp2 function prevents biliary 
excretion and increased Mrp3 protein expression at the plasma membrane increases the 
shuttling of SFB-G back into circulation.  This can be most readily seen in the Mrp2 knockout 
groups, where the genetic disruption of Mrp2 alone causes a significant increase in plasma 
SFB-G concentrations, and the addition of the MCD diet further increases the plasma retention 
of the compound.  These data, taken in conjunction with the tissue data that show an increase 
in hepatic SFB-G concentrations in Mrp2 knockout animals but a significant decrease in the 
knockout MCD group, indicates that the disruption of biliary efflux via Mrp2 is not the sole 
mediator of plasma retention of SFB-G, and that alterations to sinusoidal uptake and efflux 
during MCD diet induced NASH contributes to the changes in pharmacokinetics.  These data 
therefore confirm that the hepatocellular shuttling of SFB-G is significantly impaired during 
NASH due to disruption of the three cooperative transport mechanisms of 1) Mrp3 sinusoidal 
efflux, 2) impaired Mrp2 biliary efflux due to mislocalization, as well as 3) Oatp sinusoidal 
uptake, and quantifies the contribution of these mechanisms towards the overall changes to 
pharmacokinetics.  This elucidates the mechanistic basis behind pharmacokinetic interindividual 
variability seen in patients undergoing treatment with sorafenib or other glucuronidated 
compounds.  The disruption of the hepatocyte hopping process during NASH forms the 
underlying mechanism of pharmacokinetic alteration that has been seen in the progression of 
this disease and demonstrates the importance of the three major processes of hepatocyte 
hopping to drug disposition in human patients. 
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CHAPTER FIVE: ALTERATION OF IRON REGULATORY PROTEINS IN NONALCOHOLIC 
STEATOHEPATITIS 
Introduction 
Nonalcoholic steatohepatitis (NASH) is the more advanced form of nonalcoholic fatty liver disease 
(NAFLD). While NAFLD refers to simple steatosis, NASH presents with greater severity, with 
pathological symptoms including steatosis, fibrosis, inflammation, and significant hepatic 
oxidative stress.  Fatty liver disease is widely considered the hepatic manifestation of metabolic 
syndrome, and NAFLD is also rapidly becoming one of the most common chronic liver diseases, 
manifesting in an estimated 30-40% of adults(Clarke et al., 2013). Approximately 90% of these 
patients also exhibit at least one clinical symptom. The frequency of NASH in the population is 
estimated to be within the range of 5-17%; as NASH can only be definitively diagnosed through 
biopsy, however, true incidence rates are difficult to determine(R. Ali & Cusi, 2009; McCullough, 
2006). The progression from NAFLD to NASH is marked by the dysregulation of over 9,000 genes, 
many of which are key for absorption, disposition, metabolism, and excretion pathways(Lake et 
al., 2011). This can have serious ramifications for the disposition and toxicity of both exogenous 
and endogenous compounds. Since NASH also frequently manifests with comorbidities like 
hyperlipidemia and diabetes, it is likely that patients with NASH will also be on long-term, multi-
drug medication regiments, and thus at risk for adverse drug reactions. 
It has also been noted in the literature that a significant number of patients with chronic liver 
diseases like NASH tend to present with abnormal serum iron and hepatic iron stores; in NAFLD 
and NASH, roughly one-third and over 60% of them have increased hepatic iron concentrations, 
respectively(Bacon, Farahvash, Janney, & Neuschwander-Tetri, 1994; Nelson et al., 2011). 
These patients also tend to have increased fibrosis and histology scores, indicating that iron 
overload may contribute to the severity and pathogenesis of NASH(Bonkovsky, Banner, 
Lambrecht, & Rubin, 1996; Fargion et al., 2001; George et al., 1998). This is supported by studies 
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that have shown that iron removal via phlebotomy or chelation attenuates the progression of the 
disease(Yoshio Sumida et al., 2006; Valenti et al., 2007). Though iron is necessary for normal 
function, excess iron in hepatocytes can cause cellular damage through reactive oxygen species 
(ROS) production, which may play a role in disease progression.  
Under normal conditions, iron levels are strictly maintained to prevent the deleterious effects of 
overload or deficiency.  One of the major methods of controlling iron levels is through iron 
transport proteins. Ferroportin, a transporter protein found in hepatocytes and enterocytes, 
functions to move iron from the inside of a cell to the bloodstream. As the only known 
mammalian iron exporter, ferroportin plays a key role in the retention of iron, and dysregulation 
of the transporter can be the root cause of iron accumulation(D. Chen et al., 2007; Ward & 
Kaplan, 2012). The hormone hepcidin is the main regulator of ferroportin function, and therefore 
is one of the principal regulators of iron metabolism as a whole.  In addition to ferroportin, 
transferrin receptor-1 transports iron into hepatocytes through endocytosis of transferrin, a 
glycoprotein that contains to high-affinity Fe(III) binding sites and mediates iron concentrations 
in blood.  TfR1 is controlled post-transcriptionally by intracellular iron levels through the 
interaction of iron response proteins (IRP1/2) and the iron response element (IRE) on mRNA.  
Regulation of IRP1 comes through post-translational alterations in structure in response to the 
presence or absence of iron.  As the progression of NASH is known to result in the 
dysregulation of over 9,000 genes, it was hypothesized that NASH would disrupt the normal 
expression of genes involved in iron regulation and thus result in the hepatic iron accumulation 
seen in the disease.   
Materials and Methods 
Reagents 
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UPLC-grade water and acetonitrile, potassium ferrocyanide, hydrochloric acid, Nuclear Fast 
Red, ReadyScript cDNA synthesis kit, KiCqStart SYBR Green quantitative polymerase chain 
reaction (PCR) with low ROX master mix, and PCR primers for Bcrp and b-actin were obtained 
from Sigma-Aldrich. RNA Bee isolation reagent was obtained from Amsbio (Cambridge, MA).   
Rat and Human Liver Tissue 
Liver tissue from male Sprague-Dawley rats at 16 weeks of age that had been treated with 
either MCD diet to induce NASH or control diet was formalin-fixed and paraffin-embedded 
(FFPE).  A portion of liver tissue was also flash-frozen in liquid nitrogen and stored at -80oC.  
Sections of liver tissue were H&E stained and evaluated by a board-certified veterinary 
pathologist for disease severity according to an established rodent NASH scoring 
system(Kleiner et al., 2005).  Endpoints for NASH scoring included steatosis, necrosis, fibrosis, 
inflammation, and hyperplasia.  Rank-order statistical methods and one-way analysis of 
variance were used to determine differences between groups.  Incidence and severity scores 
were published previously(Toth et al., 2018). 
Frozen and FFPE adult human liver tissue was obtained through the Liver Tissue Cell 
Distribution System that is coordinated through the University of Minnesota, Virginia 
Commonwealth University, and the University of Pittsburgh.  The samples were scored by a 
medical pathologist within the Liver Tissue Cell Distribution System, and all scoring was 
performed according to an established NASH scoring system(Kleiner et al., 2005).  Results 
were confirmed through histological examination at the University of Arizona.  Metadata, 
including age and gender, has been previously published(Fisher, Lickteig, Augustine, Ranger-
Moore, et al., 2009).  Diagnoses consisted of: normal, steatotic, NASH with fatty liver, and 
NASH without fatty liver (NASH not fatty/cirrhosis).  Samples were diagnosed as steatotic if 
there was >10% fatty infiltration of hepatocytes, as NASH (fatty) with >5% fatty infiltration of 
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hepatocytes with significant fibrosis and inflammation, as NASH (not fatty) when fatty infiltration 
was <5% with significant inflammation and fibrotic branches. 
Quantitative Reverse-Transcription PCR 
RNA isolation from liver tissue was performed using the RNA Bee isolation reagent.  
Approximately 300 mg of liver tissue was added to 4 mL of RNA Bee, homogenized, then 
treated according to the manufacturer’s protocol.  The RNA pellet was reconstituted in 250 µL 
DEPC (diethyl decarbonate) water per 100 mg tissue, then stored at -80oC.  RNA 
concentrations were determined via NanoDrop 2000 UV-visible spectrophotometer (Thermo 
Fisher Scientific, Waltham, MA).  Final RNA preparations had a 260/280 quality ratio between 
1.6 and 1.9.  cDNA preparations were made from the isolated RNA using the ReadyScript cDNA 
synthesis kit (Sigma-Aldrich, St. Louis, MO).  Reaction wells contained 1x KiCqStart SYBR 
Green master mix, 100 nM forward/reverse primers, 2 µL cDNA template, and nuclease-free 
water.  All reactions were run in duplicate.  Reactions were run on a StepOnePlus Real Time 
PCR system (ABI, Waltham, MA) with standard SYBR green cycling profile.  Fold change was 
determined via δ-δ CT method. 
Perl’s Prussian Blue Iron Staining 
Iron staining was performed on liver sections according to the Perl’s method.  Solutions of 5% 
hydrochloric acid (HCl) and 5% potassium ferrocyanide were combined 1:1 to make the working 
solution.  Slides were deparaffinized in xylene and hydrated in distilled (DI) water, then placed in 
the working solution for 30 minutes at room temperature.  After 30 minutes, the slides were 
rinsed with DI water and then placed into nuclear fast red solution for 3 minutes.  Slides were 
then rinsed three times in DI water and dehydrated in ethanol and xylene.  The stained slides 
were then mounted with resin for microscopic analysis. 
Protein Preparation 
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Membrane and cytosolic preparations were made from frozen liver tissue.  Approximately 100 
mg of tissue was homogenized in 1 mL of cold ST buffer (sucrose Tris buffer; 10 mM Tris base 
and 250 mM sucrose) with protease inhibitor (Roche, Indianapolis, IN).  Homogenates were 
centrifuged at 10,000xg for 20 minutes to remove nuclei and then the supernatant was decanted 
into a second set of ultracentrifuge tubes. The supernatant was spun at 100,000xg for 60 
minutes to pellet the membrane fraction. The supernatant, which contains the cytosolic fraction, 
was transferred into a separate set of microcentrifuge tubes and stored at -80oC.  Membrane 
pellets were rinsed with buffer, then resuspended in 100 µl buffer and stored at -80oC.  Protein 
concentrations were determined via bicinchoninic acid assay (Thermo Fisher Scientific). 
Targeted Proteomic Quantification of Iron Regulatory Proteins 
Denaturing buffer was prepared, consisting of 3.7% sodium deoxycholate in 100mM of 
ammonium bicarbonate.  Membrane or cytosolic preparations were diluted to 300 µg in 100 µL 
of denaturing buffer.  Samples were reduced by adding DTT to a final concentration of 6 mM 
and incubated for 5 minutes at 95oC.  The samples were then alkylated by adding 
iodoacetamide to 15 mM and incubating for 30 minutes at room temperature.  Protein digestion 
was then performed using sequencing-grade trypsin at an enzyme:substrate ratio of 1:100.  
Proteins were digested in a water bath at 37oC overnight.  The next day, the reaction was 
quenched using 0.4% formic acid.  Samples were centrifuged at 16,000 xg for 30 minutes and 
the supernatant was collected, then desalted on a Waters Sep Pak C18 solid phase extraction 
cartridge (Milford, MA) as per the manufacturer’s instructions.  The eluted peptides were dried 
down using a centrivap.  Samples were then reconstituted in mobile phase and run on a Sciex 
Qtrap 6500 with triple quad LC-MS/MS system (Framingham, MA) using a Waters Acquity 
UPLC BEH C19 column (1.7μm, 2.1 x 50 mm).  Mobile phase consisted of 0.1% formic acid in 
water (A) and 0.1 % formic acid in 80% acetonitrile (B).  Runs were 30 minutes long at 0.2 
mL/min with a 10 µL injection volume.  The UPLC gradient ran at 5.5% B from 0-2 minutes, then 
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increased to 33.3% B from 2-22 minutes, held at 33% B until 24 minutes, then increased to 
100% B from 24-26 minutes.  The gradient then returned to 5.5% B from 26-28 minutes and 
maintained for 2 minutes before the start of the next run.  Raw data were analyzed using 
Analyst 1.6.2 (SCIEX, Ontario, Canada).   Protein fragments and MRM transitions can be found 
in table 1.  Statistical analyses were performed in GraphPad Prism 7. 
Statistics 
Human liver mRNA and protein data were presented as box and whisker plots comparing 
median values.  Data were analyzed using a nonparametric trend analysis with a significance 
level of p≤0.05, which allows for the determination of changes with disease progression.  
Rodent mRNA and protein data were presented as column graphs and analyzed using student’s 
t-test and presented as mean ± SD.   
Results 
Effect of Disease Progression on Human mRNA Expression 
The mRNA expression of iron regulatory genes in human liver tissue was determined via 
Affymetrix Plex 2.0 assay in normal, steatosis, NASH (fatty), and NASH (not fatty) groups (fig 
5.1).  The genes investigated included hepcidin (HAMP), ferroportin (SLC40A1), divalent metal 
transporter 1 (SLC11A2), transferrin receptor-1 (TFRC), transferrin (TF), ferritin heavy and light 
chain (FTH, FTL), and iron response binding protein (ACO1). The only significant trends seen in 
the data were for HAMP, SLC11A2, and ACO1, the expression of which decreased throughout 
the progression of the disease.  TFRC, TF, and FTH appeared to have an increasing trend from 
normal to NASH (fatty), but the trend was not statistically significant. 
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Effect of Disease Progression on Human Protein Expression 
Protein expression of iron regulatory proteins was determined by targeted proteomic 
analysis in normal, steatosis, NASH (fatty), and NASH (not fatty) groups (fig 5.2).  The proteins 
investigated included hepcidin (HEPC), ferroportin (FPN), divalent metal transporter 1 (DMT1), 
Fig. 5.1. Altered mRNA expression during the progression of NASH in human liver tissue.  Transcriptomic analysis of 
human liver samples was done by Affymetrix chip and previously published.  Expression change was determined using 
nonparametric trend analysis.  Data represents mean ± SD, n=10. 
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transferrin receptor-1 (TFRC), transferrin (TRFE), ferritin heavy chain (FtH), and ferritin light 
chain (FtL), and the proteins were normalized to either the sodium-potassium pump (Na+/K+-
ATPase) in the case of membrane proteins, or to cyclophillin A for cytosolic proteins.  
Mass/charge ratios and retention times can be found in table 1.  Of these proteins, TRFE, 
TFR1,FtH, and FtL increased in expression with disease progression, while HEPC, DMT1, and 
FPN showed a decreasing trend.   
 
 
Effect of Disease Progression on Human Hepatic Iron Levels 
Perl’s Prussian blue iron stain was used to assess the amount of ferric iron deposits within 
human hepatocytes in normal, steatotic, NASH (fatty), and NASH (not fatty) patient groups (fig 
5.3).  The percent of stained tissue was determined by assessing the area of stained tissue 
Fig 5.2.  Altered protein expression during the progression of NASH in human liver tissue.  Relative protein 
expression in human liver tissue was determined via proteomic analysis using LC-MS/MS and normalized to 
Na+/K+-ATPase or Cyclophilin A (PPIA) expression.  Data represents mean ± SD, n=10. 
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divided by total tissue area (fig 5.4).  Trend analysis determined an increase in iron deposits as 
the disease progressed. 
 
 
 
Fig 5.3.  Altered protein expression during the progression of NASH in human liver tissue.  Relative protein 
expression in human liver tissue was determined via proteomic analysis using LC-MS/MS and normalized to 
Na+/K+-ATPase or Cyclophilin A (PPIA) expression.  Data represents mean ± SD, n=10. 
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Effect of NASH on Rat mRNA Expression 
The mRNA expression of iron regulatory genes in rat liver tissue was determined via qRT-PCR 
in normal and MCD diet-induced NASH animals (fig 5.5).  The genes investigated included 
(Hamp), ferroportin (Slc40a1), divalent metal transporter 1 (Slc11a2), transferrin receptor-1 
(Tfrc), transferrin (Tf), and iron response binding protein (Aco1).  Between the control and MCD 
groups, the mRNA expression changes were as follows: the expression of Hamp increased by 
2-fold, of Slc40a1 increased by 1.6-fold, of Slc11a2 increased by 1.5-fold, of Tfrc decreased by 
0.24-fold, of Tf increased by 2.4-fold, and of Aco1 increased by 2.5-fold. 
Fig. 5.4.  Percent area of Perl’s Prussian blue iron staining in liver tissue.  Percentage of stained area on histology 
slides was determined by stained area/total area in A) human and B) rat liver tissue sections.  Change in percent area 
was determined using nonparametric trend analysis for human samples and student t-test for rat samples.  Data 
represents mean ± SD, n=10 for human, n=5 for rat.  * P≤.05. 
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Effect of NASH on Rat Protein Expression 
Protein expression of iron regulatory proteins was determined by targeted proteomic 
analysis in normal, steatosis, NASH (fatty), and NASH (not fatty) groups (fig 5.6).  The proteins 
investigated included hepcidin (Hepc), ferroportin (Fpn), divalent metal transporter 1 (Dmt1), 
transferrin receptor-1 (Tfrc), transferrin (Trfe), ferritin heavy chain (Fth), and ferritin light chain 
(Ftl), and the proteins were normalized to either the sodium-potassium pump (Na+/K+-ATPase) 
Fig. 5.5.  Altered mRNA expression in rodent diet-induced NASH.  mRNA expression was determined through 
qRT-PCR and fold change was determined using the ΔΔCT method.  Data represents mean ± SD, n=5.  * P≤.05, ** 
P≤.01, *** P≤.001. 
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in the case of membrane proteins, or to cyclophillin A for cytosolic proteins.  Mass/charge ratios 
and retention times can be found in table 1.  Of the proteins investigated, Fth and FtL 
expression in the MCD group decreased to 59% and 53% of control, respectively, and Fpn 
increased to 500% of control.  No significant changes were observed in Hepc or Trfe 
expression.   
Effect of NASH on Rat Hepatic Iron Levels 
Perl’s Prussian blue iron stain was used to assess the amount of ferric iron deposits 
within rat hepatocytes in control and MCD diet-induced NASH animals (fig 5.3).  Percent of 
stained tissue was determined by dividing the area of the stained tissue by the total tissue area.  
Iron deposits in the MCD diet-induced NASH rats increased by 3.2-fold when compared to 
controls.   
 
 
 
 
Fig. 5.6.  Altered protein expression in rodent diet-induced NASH.  Relative protein expression was determined 
by proteomic analysis using LC-MS/MS and normalized to to Na+/K+-ATPase expression.  Data represents mean ± 
SD, n=5.  * P≤.05, ** P≤.01. 
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Peptide Sequence Q1 Mass Q3 Mass 
Hepcidin K.TDDSALLMLK.R 553.7 688.4 
FPN (h) K.SVPIISVSLLFAGVIAAR.I 907.0 1030.6 
Fpn (r) K.SVPIISVSLLFAGVIAAR.I 907.0 917.5 
FTH (h) R.DDWESGLNAMR.C 647.2 661.3 
Fth (r) K.MGAPESGMAEYLFDK.H 823.3 1016.4 
FTL (h) R.ASYTYLSLGFFFDR.D 843.9 901.4 
Ftl (r) K.TLEAMEAALALEK.N 695.3 715.4 
DMT1 (h) K.LLWVLLLATIVGLLLQR.L 967.6 1012.6 
Dmt1 (r) K.LLWVLLLATIVGLLLQR.L 967.6 1196.7 
TRFE (h) K.SASDLTWDNLK.G 625.3 675.3 
Trfe (r) K.ASDSSINWNNLK.G 674.8 901.4 
TFR1 K.AFTYINLDK.V 542.7 765.4 
PPIA K.EGMNIVEAMER.F 639.7 961.4 
Na+/K+ATPase R.AAVPDAVGK.C 414.2 586.3 
 
Discussion 
It is not uncommon for patients with chronic liver diseases, including NASH, to present with 
atypical serum iron and hepatic iron overload.  Approximately 60% of NASH patients present 
with abnormally high hepatic iron stores, and these patients also tend to present with increased 
fibrosis histology scores(Bacon et al., 1994; Bonkovsky et al., 1996; Fargion et al., 2001; 
George et al., 1998; Nelson et al., 2011).  This iron overload may be a contributing factor to the 
progression of NAFLD to NASH, especially as iron removal via phlebotomy has been shown to 
reduce the NAS scores of biopsy-verified NASH patients(Yoshio Sumida et al., 2006; Valenti et 
al., 2007).  The attenuation of the disease that occurs post-phlebotomy treatments may be due 
Table 5.1. Peptide Fragments and MRM Transitions for LC-MS/MS Analysis. 
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to the reduction of labile iron pools within hepatocytes; free iron can participate in Fenton 
reactions within the cell, producing hydroxyl radicals that can cause cellular damage.  Certain 
liver enzymes also require iron-containing heme cofactors to function, and therefore produce 
reactive oxygen species during their normal function.   
 Hepatic iron stores are tightly regulated in order to prevent the deleterious 
consequences associated with iron overload.  As there are limited ways to remove iron from the 
body after it has been absorbed, much of the mechanisms that regulate it are either associated 
with transporting iron or sequestering it in storage proteins.  One of the major transporters 
involved in the movement of iron is ferroportin, a transmembrane protein found in a variety of 
cells, including hepatocytes and enterocytes.  This protein is the only known mammalian iron 
exporter, and therefore plays a key role in managing the intracellular concentrations of iron, and 
dysregulation of this protein can have significant impacts on iron stores(D. Chen et al., 2007; 
Ward & Kaplan, 2012).  Ferroportin is negatively regulated by hepcidin, a hormone produced by 
the liver that binds to the active site of ferroportin and causes its internalization(Bogdan et al., 
2016; Nemeth & Ganz, 2006).   
Transferrin receptor-1, on the other hand, is the major mediator of iron uptake by 
hepatocytes through the binding of transferrin, an iron carrier glycoprotein.  The process by 
which transferrin receptor-1 internalizes iron-laden transferrin has been extensively studied.  
When diferric TF binds to TfR1, the glycoprotein and the receptor are internalized in a clathrin-
coated pit via endocytosis.  The resulting endosome undergoes a drop in pH, which causes a 
structural change in TF.  The histidine349 residue of TF and the tryptophan641 and 
phenylalanine760 residues of TfR1 interact and trigger the transformation, which then results in 
the release of iron from TF.  The TF-TfR1 complex is then recycled back to the surface of the 
cell, where TF is released back into circulation and TfR1 returns to its membrane 
localization(Daniels, Delgado, Rodriguez, Helguera, & Penichet, 2006).  Alterations to this 
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mechanism either through TF or TfR1 could result in significant dysregulation of iron uptake and 
intracellular iron concentrations.  This is particularly relevant for TfR1, as its expression is 
primarily mediated through post-transcriptional modifications rather than transcriptional 
regulators.  TfR1 is mediated by the binding of iron response proteins to the iron response 
element (IRE) on its mRNA, as is the only known protein to contain multiple of these IRE 
hairpins.  Binding of IRPs to these hairpins stabilizes the mRNA and allows for its translation 
into protein(PANTOPOULOS, 2004).  IRPs themselves are regulated directly by iron, as they 
undergo conformational changes when in the presence of high or low iron concentrations; 
however, IRPs can be activated by ROS, which could result in inappropriate binding to IREs in 
conditions of high oxidative stress, such as chronic liver diseases(Mueller et al., 2001; 
Pantopoulos & Hentze, 1998).   
It has been known for some time that chronic liver diseases impact hepatic iron levels, 
and the purpose of this study is to describe the alterations to hepatic iron regulator proteins that 
occur during the progression of NASH in human patients and the rodent MCD model.  Perl’s 
Prussian blue iron staining revealed that there is a trend of increasing hepatic iron deposition 
during the progression of the disease, which is recapitulated in the rodent MCD model of NASH.  
Transcriptomic analysis of human samples also determined that several genes responsible for 
mediating iron regulation are altered during NASH, including ACO1, HAMP, and DMT1.  These 
changes, however, were not reflected in the MCD model, which instead presented with 
upregulation of Fpn, Hamp, Dmt1, Tf, and Aco1 and downregulation of TfR1.  The protein 
expression of these iron proteins was also incongruent between the human disease and animal 
model; in human patients, TFR1, TRFE, FTH, and FTL were upregulated, and HEPC, FPN, and 
DMT1 were downregulated.  In the MCD rat model, only Fth and Ftl were downregulated, while 
Fpn was upregulated.  These differences between human and MCD diet-induced NASH likely 
arise from the disparate pathogenesis between the human disease and the MCD model.  While 
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the development of NASH in humans is a complex process that takes many years to manifest 
and involves comorbidities and other complicating factors, the MCD diet utilizes methionine and 
choline deficiency to impair the hepatic production and secretion of very-low-density lipoprotein 
(VLDL), alter mitochondrial bioenergetics and fatty acid β-oxidation, and disrupt hepatic methyl 
balance(Li, Toth, et al., 2017).  Though the end result of the MCD diet is a liver that 
histologically mirrors human NASH and presents with similar alterations to hepatic xenobiotic 
transporter proteins, its pathogenesis mechanisms are otherwise dissimilar and do not result in 
the same alterations to iron regulatory proteins as human NASH.  Other rodent models that 
more closely mimic the human pathogenesis of NASH may provide better insights into the 
mechanisms of iron regulation during the disease than the MCD model. 
 While it is unlikely that dysregulation of any one individual iron regulatory protein is 
solely responsible for the increase in hepatic iron seen in NASH human tissue, alterations to 
several of them are likely contributory factors.  Increases in TfR1 protein expression in NASH, 
possibly due to ROS activation of ACO1 or post-translational modifications that prolong the half-
life of the protein, along with increased TRFE expression could result in increased iron import 
into hepatocytes, while decreased ferroportin expression may contribute to the hepatic 
accumulation of iron through reduced efflux.  Decreased serum hepcidin also results in 
increased intestinal absorption by increasing FPN expression in the duodenum, as has been 
seen in chronic hepatitis C patients(Sato et al., 2018). While the upregulation of ferritin subunits 
would indicate increased iron storage potential in the hepatocyte, the high oxidative stress that 
occurs during NASH(R. N. Hardwick et al., 2010; Y Sumida, Niki, Naito, & Yoshikawa, 2013) 
inhibits ferritin’s ability to sequester iron.  The heavy subunits of ferritin have ferroxidase activity 
to convert iron from the ferrous to the more stable ferric form for storage. When antioxidants are 
depleted, as in conditions of high oxidative stress, ferroxidase activity becomes downregulated, 
preventing the removal of ferrous iron from iron pools in the cell. Additionally, a rapid release of 
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iron from ferritin occurs during these conditions due to increasing reducing potential and 
anaerobiosis.(Manuel Fernandez-Real et al., 2002)  Overall, then, the iron storage capacity of 
ferritin would likely be reduced in NASH despite upregulation of protein expression due to high 
oxidative stress.  Though this research gives some insight into the potential alterations to iron 
regulation that may drive the hepatic iron accumulation seen in human NASH patients, further 
investigation is necessary to pinpoint the responsible mechanisms.  
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CHAPTER SIX: CURRENT PERSPECTIVES AND FUTURE DIRECTIONS 
Summary of Studies 
Alterations to hepatic uptake and efflux transporters are responsible for variable drug 
response in human patients, as many compounds rely on active transport for their disposition 
and elimination.  The extensive remodeling of ADME processes that occurs during the 
progression of NASH also dysregulates the expression of hepatic uptake and efflux 
transporters, resulting in pharmacokinetic alterations.  While simple genetic polymorphisms or 
NASH alone can be sufficient to cause changes to disposition, the interaction between genes 
and disease state can result in pharmacokinetic alterations that are greater than the sum of their 
parts.  The purpose of this doctoral work was to determine the impact of synergistic gene-by-
environment interactions between NASH and polymorphisms of hepatic uptake and efflux 
transporters on drug disposition and to determine the underlying mechanism of altered 
pharmacokinetics in NASH. 
Chapters 2 and 3 investigated the impact of genetic polymorphisms of Bcrp and Oatp1b2 
and NASH on drug disposition using the MCD rodent model.  The results in this model indicate 
that the combination of a full genetic knockout with NASH is sufficient to cause significant 
pharmacokinetic alterations, potentially increasing the risk of toxicity.  In the Bcrp study, the 
combination of Bcrp-/- and NASH resulted in a dramatic decline in biliary excretion of both parent 
compound and metabolite, demonstrating the both a compensatory mechanism by which the 
liver can upregulate Bcrp expression in order to offset the decrease in function of the 
mislocalized Mrp2 transporter as well as the synergistic gene-by-environment interaction. In the 
Oatp1b2 gene dose study, the Oatp1b2-/+ mice showed no significant alterations to plasma AUC 
or tissue concentrations; the full genetic knockout was necessary to observe altered 
pharmacokinetics.  This is likely due to the upregulation of Oatp1a4 during NASH, which can 
participate enough in the transport of pravastatin to avoid significant pharmacokinetic 
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consequences so long as there is some amount of function Oatp1b2.  The loss of compensatory 
transport through genetic polymorphisms during NASH disrupts normal disposition and 
elimination, resulting in increases in plasma retention and potentially increased risk of toxicity for 
patients. 
 In chapter 4, the underlying mechanism by which alterations to hepatic uptake and efflux 
transporters impact pharmacokinetics was described through the use of the MCD diet in 
combination with Oatp1a/1b cluster knockouts and Mrp2 knockouts.  The disposition of SFB-G 
is mediated through Oatps, Mrp3, and Mrp2, though the sinusoidal uptake and efflux 
transporters are the major players in the hepatocyte hopping pathway, as disruption of Oatps 
would prevent downstream reuptake and upregulation of Mrp3 would increase efflux into 
plasma.  The reduction in hepatic uptake due to either the Oatp1a/1b cluster knockout or the 
MCD diet resulted in plasma retention of SFB-G, as did the Mrp2 knockout; the addition of the 
MCD diet with the Mrp2 knockout, however, also showed a significant increase in the plasma 
concentrations of SFB-G, representing the impact of the decreased Oatp expression and 
increased Mrp3 expression that occurs during NASH on plasma concentrations.  These data, 
when taken with the liver tissue concentration data that showed an increase in hepatic SFB-G 
concentration in the Mrp2 knockout but decreased concentration in the Mrp2 knockouts with 
NASH, indicate that sinusoidal uptake and efflux transporters are mediators of hepatocyte 
hopping, not Mrp2, and that pharmacokinetic interindividual variability seen in NASH patients is 
due to disruption of the hepatocyte hopping mechanism.  As the Oatp and Mrp transporters 
have broad substrate specificities, and many pharmaceutical compounds undergo 
glucuronidation, it is likely that a wide range of therapeutics would be affected by the disruption 
of hepatocyte hopping during this disease. 
The purpose of chapter 5 was to investigate the impact of NASH on hepatic iron regulatory 
mechanisms, including transporters, iron storage proteins, and other mediators.  It was 
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determined that the progression of NASH resulted in the hepatic accumulation of iron in both 
human NASH and the MCD rodent model, and that the disease also caused alterations to 
mRNA and protein expression of iron transport and storage proteins.  While NASH impacted 
expression in both the human disease and the MCD diet rats, the specific alterations to iron 
regulatory proteins was disparate between those two groups, and the MCD diet did not 
adequately reflect the changes that were found in the human disease.  This was likely due to 
the inherent differences in the pathogenesis of NASH in humans and the MCD diet.  Though the 
hepatic iron accumulation could not be fully explained by the mRNA and protein alterations 
observed in the human disease, some insight could be gained on the contributory factors that 
may impact the increased iron concentrations observed in human NASH liver tissue.    
Future Directions 
Renal ADME Alterations During NASH 
 There has been significant research in recent years on the impact of crosstalk between 
the liver and kidney and the relationship between liver function and kidney dysfunction.  
Hepatorenal syndrome is one notable example, where acute renal injury occurs secondary to 
cirrhosis due to circulatory changes that cause vasoconstriction in the kidney.  There is also 
some evidence that NAFLD and NASH may result in kidney injury through the release of 
inflammatory cytokines, ROS, and other deleterious mediators.   
Findings from the Cherrington lab also have indicated that there may be alterations to 
renal kidney transporter expression as a compensatory mechanism for the decreased 
hepatobiliary excretion seen during NASH.  The disposition of metformin, which is primarily 
eliminated through renal excretion, has been shown to be altered in the diabetic ob/ob mouse 
model of NASH, and a previous study with adefovir indicated that there was a decreased filtrate 
rate but increased secretion rate of the compound in the NASH model(Clarke et al., 2015; Laho 
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et al., 2016).   This indicates that NASH significantly impacts transport mechanisms in the 
kidney and could thus contribute to the inter-individual variability of drug response in human 
patients. 
 This study endeavors to identify the impact of NASH on renal function in human patients, 
as these changes may significantly impact the fate of drug therapies.  There is little information 
on the effect on NASH on renal filtration and secretion, despite the potential influence on the 
risk of toxicity in certain patient populations.  It is therefore hypothesized that NASH alters the 
expression and function of renal xenobiotic transporter proteins, changing the pharmacokinetics 
of drug therapies in NASH patients and increasing the risk of adverse drug reactions.   The 
following aims intend to test the hypothesis: 
Aim 1.  Determine the changes in expression and localization of renal transporter enzymes in 
human NASH patients 
 A collection of kidney tissue from biopsy-verified NASH and normal patients is available 
to the Cherrington lab.  The mRNA and protein expression of transporters of interest, including 
but not limited to OAT1, OAT3, OCT1, OCT2, MATE1, MATE2-K, BCRP, MRP4, and various 
OATPs, will be determined through transcriptomic and proteomic analyses.   
Aim 2: Determine the functional changes in individual secretion pathways and resulting potential 
for toxicity in a rodent model of NASH 
 Using the data gained from Aim 1, an appropriate animal model of NASH will be 
selected from a pool of potential models based on which best recapitulates the mRNA and 
protein changes observed in the human disease.  A battery of transport studies will then be 
conducted to assess secretion pathways.  An appropriate probe compound will be used in the 
animal model to determine the impact of NASH on toxic potential. 
Aim 3: Determine the impact of NASH on GFR and secretion in human patients 
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 Bariatric surgery volunteers will be recruited with the help of surgeon collaborators for a 
clinical study.  Patients will be categorized into NASH or not NASH groups, then a 
subtherapeutic dose of a probe cocktail of adefovir and metformin, along with a dose of iohexol 
to determine GFR, will be administered, with urine and plasma being collected for a period of 10 
hours after dosing.  Anticipated results include decreased GFR in the NASH patients, with 
altered pharmacokinetics of adefovir and metformin following the changes in transporter 
expression as determined in Aim 1. 
Iron Regulation in NASH 
 The progression of NASH, as with other chronic liver diseases, results in the increased 
deposition of iron in hepatocytes.  The increased labile iron pools have the potential to 
participate in Fenton reactions, thereby producing reactive oxygen species and compounding 
oxidative stress in the cells, potentially exacerbating the disease.  It has been previously found 
that the progression of NASH causes alterations to the mRNA and protein expression of iron 
transport and storage mediators in the liver, which likely contribute to the aberrant iron levels 
found in human NASH hepatocytes.   These changes do not entirely explain the accumulation 
observed in hepatocytes, however, nor does the commonly used MCD rodent model of NASH 
recapitulate the human alterations.  Therefore, further research is necessary to probe the 
mechanisms behind the dysregulated iron storage in NASH and to determine an animal model 
that would be more appropriate for studying iron regulation in NASH than the MCD model. 
 Many factors beyond the transcriptional can influence the expression of a particular 
protein; in the case of iron transport and storage proteins, the IREB/ACO1 iron response binding 
factor plays a major role in up- or down-regulating proteins involved in iron storage, and post-
translational modifications like glycosylation are important for the appropriate localization of 
transporter proteins like ferroportin or DMT1.  While it has been previously determined that the 
glycosylation of some transporter proteins is decreased in NASH and this may impact their 
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proper function and localization(Clarke, Novak, Lake, Hardwick, & Cherrington, 2017), there is a 
dearth of information on the glycosylation status of FPN, DMT1, and TfR1 during the disease.  
The glycosylation status is particularly important for the function of DMT1 and TfR1, as TfR1 
has a critical glycosylation and the affinity of DMT1 for iron is altered based on 
glycosylation(Dunham et al., 2018; Zhao & Enns, 2013).  Other post-translational modifications, 
like phosphorylation and ubiquitination(Czuba, Hillgren, & Swaan, 2018; Ward & Kaplan, 2012).  
Additionally, there is some evidence that increased oxidative stress can alter the ferroxidase 
activity of ferritin, preventing iron storage within the protein complex.  These non-transcriptional 
mechanisms thus may contribute to the hepatic iron accumulation seen in NASH. 
 While the MCD diet may have utility for investigating pharmacokinetic alterations in 
NASH due to transporter alterations, it does not successfully recapitulate the disease in any 
other facet(Li, Toth, et al., 2017).  Other diet-induced NASH models may have greater success 
at modeling the changes that occur during this disease to other pathways, including iron 
regulation.  Long-term high fat/high fructose diets are known to induce NASH in rodent models, 
and these animals also exhibit similar perturbations to lipid metabolism and insulin sensitivity 
that is found in human NASH patients(Dowman et al., 2014).   As these diets more faithfully 
reproduce the pathogenesis of NAFLD and NASH in the rodent model, there is a greater 
likelihood that it may also alter the pathways involved in iron regulation in a similar pattern to 
human patients. 
 This study aims to identify the mechanisms behind the hepatic iron accumulation found 
in human NASH and to determine an effective rodent model that recapitulates the changes seen 
in the human disease.  It is hypothesized that NASH causes alterations to IREB/ACO1 binding 
activity, post-translational modifications to transporter proteins such as glycosylation, 
phosphorylation, and ubiquitination, and ferroxidase activity of ferritin, and that the changes to 
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iron regulation observed in human NASH will be recapitulated in a long-term high fat/high 
fructose rodent diet model. 
 Aim 1.  Determine the changes to the functional activity of IREB/ACO1 binding and 
ferroxidase in human NASH 
 Liver tissue from biopsy-verified NASH patients is available to the Cherrington lab.  
Aconitase activity kits are commercially available and will determine the activity of IREB/ACO1 
in these samples.  Ferroxidase activity of ferritin will be determined through the transferrin 
reaction(Bakker & Boyer, 1986).   
 Aim 2.  Determine the changes to post-translational modifications of iron regulatory 
proteins in human NASH 
 Using the available human samples, the mRNA and protein expression of glycosylation 
mediatiors, kinases, and ubiquitin ligases will be determined through PCR and targeted 
proteomic LC-MS/MS analysis.  Targeted proteomic LC-MS/MS analysis will also be used to 
determine the ratio of modified protein to unmodified protein during the progression of the 
disease. 
 Aim 3.  Characterize the alterations to iron regulation in a high fat/high fructose NASH 
rodent diet 
 With the data gained from the human NASH patients in Aim 1 and Aim 2, and from data 
gained in previous studies, diet-induced rodent NASH models can be assessed to determine 
which best recapitulates the changes seen in human disease.    
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